1
|
Cerdido S, Abrisqueta M, Sánchez-Beltrán J, Lambertos A, Castejón-Griñán M, Muñoz C, Olivares C, García-Borrón JC, Jiménez-Cervantes C, Herraiz C. MGRN1 depletion promotes intercellular adhesion in melanoma by upregulation of E-cadherin and inhibition of CDC42. Cancer Lett 2024; 581:216484. [PMID: 38008393 DOI: 10.1016/j.canlet.2023.216484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Revised: 10/25/2023] [Accepted: 11/03/2023] [Indexed: 11/28/2023]
Abstract
Mahogunin Ring Finger 1 is an E3-ubiquitin ligase encoded by the color gene MGRN1. Our previous in vitro and in vivo studies demonstrated that Mgrn1 deletion in mouse melanoma cells induced cell differentiation and adhesion, and decreased cell motility and invasion on collagen I, and lung colonization in an in vivo model. Here, we investigated the role of MGRN1 on human melanoma cell morphology, adhesion and expression of genes/proteins involved in an EMT-like transition. We demonstrated that wild-type BRAF human melanoma cells adopted a clustering-like morphology on collagen I, with permanent MGRN1 abrogation resulting in bigger cell clusters. Enhanced intercellular adhesion was mostly mediated by induction of E-cadherin and higher co-localization with β-catenin. Transcriptional upregulation of E-cadherin likely occurred through downregulation of the ZEB1 repressor. Finally, pulldown assays showed reduced activation of CDC42 in the absence of MGRN1, which was reverted after E-cadherin silencing. Overall, these findings highlight a new MGRN1-dependent pathway regulating melanoma cell shape, motility, and invasion potential.
Collapse
Affiliation(s)
- S Cerdido
- Department of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB), 30120, Murcia, Spain
| | - M Abrisqueta
- Department of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB), 30120, Murcia, Spain
| | - J Sánchez-Beltrán
- Department of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB), 30120, Murcia, Spain
| | - A Lambertos
- Department of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB), 30120, Murcia, Spain
| | - M Castejón-Griñán
- Department of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB), 30120, Murcia, Spain
| | - C Muñoz
- Department of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB), 30120, Murcia, Spain
| | - C Olivares
- Department of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB), 30120, Murcia, Spain
| | - J C García-Borrón
- Department of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB), 30120, Murcia, Spain
| | - C Jiménez-Cervantes
- Department of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB), 30120, Murcia, Spain
| | - C Herraiz
- Department of Biochemistry, Molecular Biology and Immunology, School of Medicine, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB), 30120, Murcia, Spain.
| |
Collapse
|
2
|
Clavijo MM, Ruiz JI, Muñoz C, Vicente Reparaz M de Los A, Acuña MA, Casali CE, Aizpurua MF, Mahuad CV, Zerga ME, Ventura A, Garate GM. Use of direct oral anticoagulants and low molecular weight heparin in venous thromboembolism associated with cancer: real-world evidence in Argentina. Expert Rev Hematol 2023; 16:1143-1149. [PMID: 37955142 DOI: 10.1080/17474086.2023.2281945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Accepted: 10/22/2023] [Indexed: 11/14/2023]
Abstract
BACKGROUND Venous thromboembolism (VTE) and major bleeding (MB) are common in cancer patients. Reduced-doses of antithrombotics as secondary prophylaxis have limited data. This work aims to describe and to compare treatments and outcomes for cancer-associated VTE. RESEARCH DESIGN AND METHODS Retrospective study. Adults with cancer-associated VTE were included. After 3-6 months of full-doses of anticoagulants, three strategies were considered: A) lowering the doses; B) maintaining full-doses; C) stopping treatment. The strategy and medication used were shown in a descriptive analysis and the rate of bleeding and VTE-recurrence between those in a comparative analysis. RESULTS A total of 420 patients were included, 56.2% received DOACs, 43.8% enoxaparin. Strategy was defined in 257 patients: A (50.2%), B (46.3%), and C (3.5%). Forty-one (9.8%) had VTE-recurrence and 15 (3.6%) had MB or clinically relevant non-major bleeding (CRNMB).According to strategy, recurrent-VTE was 8.5% (A), 4.2% (B), and 11.1 (C) (p = 0.22), MB or CRNMB was 0.8% (A), 1.7% (B), and 0% (C) (p = 0.64). CONCLUSIONS DOACs and strategy A were the most frequently used agent and strategy, respectively. There were no differences between medications or strategies used. The results must be interpreted with caution, and it is a retrospective single-center study, probably with information and selection bias.
Collapse
Affiliation(s)
- M M Clavijo
- Hematology and Oncology, Hospital Aleman, Buenos Aires, Argentina
| | - J I Ruiz
- Anderson Cancer Center, Department of Health Services Research, Division of Cancer Prevention and Population Sciences, Houston, TX, USA
| | - C Muñoz
- Hematology and Oncology, Hospital Aleman, Buenos Aires, Argentina
| | | | - M A Acuña
- Hematology and Oncology, Hospital Aleman, Buenos Aires, Argentina
| | - C E Casali
- Hematology and Oncology, Hospital Aleman, Buenos Aires, Argentina
| | - M F Aizpurua
- Hematology and Oncology, Hospital Aleman, Buenos Aires, Argentina
| | - C V Mahuad
- Hematology and Oncology, Hospital Aleman, Buenos Aires, Argentina
| | - M E Zerga
- Hematology and Oncology, Hospital Aleman, Buenos Aires, Argentina
- Hematology, Angel A. Roffo Institute of Oncology, Buenos Aires, Argentina
| | - A Ventura
- Hematology and Oncology, Hospital Aleman, Buenos Aires, Argentina
| | - G M Garate
- Hematology and Oncology, Hospital Aleman, Buenos Aires, Argentina
| |
Collapse
|
3
|
Londoño J, Perez L, Moreno S, Chapman E, Garcia MB, Celis AM, Muñoz MA, Castillo D, Sánchez J, Arevalo Y, Lozano A, Alvis-Zakzuk NJ, Muñoz C, Botero L, Beltran C, García E. Effectiveness and safety of dupilumab in adults with moderate and severe atopic dermatitis in Colombia: Real-life experience. World Allergy Organ J 2023; 16:100763. [PMID: 37091550 PMCID: PMC10113899 DOI: 10.1016/j.waojou.2023.100763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 02/20/2023] [Accepted: 03/12/2023] [Indexed: 04/25/2023] Open
Abstract
Background Dupilumab is a treatment approved for uncontrolled moderate-to-severe atopic dermatitis (AD). Tropical and developing countries such as Colombia have characteristics that may impact the natural history of AD and access to medical treatments. In that sense, we aimed to describe the effectiveness and safety of dupilumab in adults with moderate to severe AD in a Colombian multicenter cohort. Methods Multicenter descriptive study that included patients who started treatment between March 2018 and May 2020 in 6 centers. Disease severity was assessed using the following: Scoring Atopic Dermatitis (SCORAD), Eczema Area and Severity Index (EASI), Patient Oriented Eczema Measure (POEM), and Dermatology Life Quality Index (DLQI). These measurements were collected according to availability at baseline, 3-5 months, 6-12 months, and more than 12 months. Days of sick leave, hospitalizations, and AD flares before and after dupilumab treatment were reported. Adverse events (AEs) were recorded during follow-up. Results Ninety-three patients were included, with a median age of 32 years (IQR: 24.0; 40.0) and a disease evolution time of 21 years (IQR: 16.0; 29.5). 88.2% had at least 1 allergic disease other than AD. An improvement greater than or equal to 75% EASI was observed in 41.7% of patients at 3-5 months, in 73.7% of patients at 6-12 months, and in 75.0% of patients after 12 months. For those reporting SCORAD and POEM, the median percent change ([IQR], n) from baseline in SCORAD was -67.1 ([-79.2; -54.2], n = 16), -70.5 ([-85.8; -47.9], n = 36) and -66.7 ([-77.3; -51.0], n = 13); and POEM, -58.6 ([-66.4; -55.5], n = 4), -73.0 ([-86.5; -66.7], n = 16) and -87.3 ([-93.4; -69.6], n = 8), respectively. Before initiation of dupilumab treatment, 82 (88.2%) patients reported at least 1 flare of AD in the past 12 months. During the follow-up period, 30 (32.3%) patients reported at least 1 exacerbation or flare. Twelve patients (12.9%) presented an AE and 3 (3.2%) patients discontinued dupilumab for this cause. Conclusions Dupilumab was effective and safe for the treatment of moderate to severe AD in point-of-care settings, with results similar to randomized controlled and other real-life studies. These positive results are still maintained even though a high number of patients had short interruptions in the use of dupilumab due to administrative problems.
Collapse
Affiliation(s)
| | - Lucia Perez
- Allergy Research Group, UNIMEQ-ORL, Bogotá, Colombia
| | - Sergio Moreno
- Allergy Research Group, UNIMEQ-ORL, Bogotá, Colombia
- School of Medicine, Universidad de Los Andes Bogotá, Colombia
| | - Edgardo Chapman
- Allergy Research Group, UNIMEQ-ORL, Bogotá, Colombia
- Allergy Section, Fundación Santa Fe de Bogotá, Bogotá, Colombia
| | - María Beatriz Garcia
- Allergy Research Group, UNIMEQ-ORL, Bogotá, Colombia
- Allergy Section, Fundación Santa Fe de Bogotá, Bogotá, Colombia
| | | | | | | | - Jorge Sánchez
- Group of Clinical and Experimental Allergy - Hospital "Alma Mater de Antioquia", University of Antioquia, Medellín, Colombia
- Medellín Allergology Unit, Medellín, Colombia
- Clinical and Experimental Allergology Group, Universidad de Antioquia Medellín, Colombia
| | | | | | | | - Cesar Muñoz
- Clínica Respiratoria y de Alergias SAS Cartagena, Colombia
| | | | | | - Elizabeth García
- Allergy Research Group, UNIMEQ-ORL, Bogotá, Colombia
- Allergy Section, Fundación Santa Fe de Bogotá, Bogotá, Colombia
- School of Medicine, Universidad de Los Andes Bogotá, Colombia
- Corresponding author.
| |
Collapse
|
4
|
Undurraga P, Dreyse J, Melo J, Lazo D, Rodriguez H, Gaete P, Perez E, Mora J, Morales Melgarejo C, Muñoz C, Gatica A, Seguel N, Calabran L, Alarcon P, Valverde C. Pediatric Lobar Lung Transplantation (plltx): Increasing Utilization of Lung in a Low Donation Rate Country. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
5
|
Bougouin A, Hristov A, Dijkstra J, Aguerre MJ, Ahvenjärvi S, Arndt C, Bannink A, Bayat AR, Benchaar C, Boland T, Brown WE, Crompton LA, Dehareng F, Dufrasne I, Eugène M, Froidmont E, van Gastelen S, Garnsworthy PC, Halmemies-Beauchet-Filleau A, Herremans S, Huhtanen P, Johansen M, Kidane A, Kreuzer M, Kuhla B, Lessire F, Lund P, Minnée EMK, Muñoz C, Niu M, Nozière P, Pacheco D, Prestløkken E, Reynolds CK, Schwarm A, Spek JW, Terranova M, Vanhatalo A, Wattiaux MA, Weisbjerg MR, Yáñez-Ruiz DR, Yu Z, Kebreab E. Prediction of nitrogen excretion from data on dairy cows fed a wide range of diets compiled in an intercontinental database: A meta-analysis. J Dairy Sci 2022; 105:7462-7481. [PMID: 35931475 DOI: 10.3168/jds.2021-20885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2021] [Accepted: 04/03/2022] [Indexed: 11/19/2022]
Abstract
Manure nitrogen (N) from cattle contributes to nitrous oxide and ammonia emissions and nitrate leaching. Measurement of manure N outputs on dairy farms is laborious, expensive, and impractical at large scales; therefore, models are needed to predict N excreted in urine and feces. Building robust prediction models requires extensive data from animals under different management systems worldwide. Thus, the study objectives were (1) to collate an international database of N excretion in feces and urine based on individual lactating dairy cow data from different continents; (2) to determine the suitability of key variables for predicting fecal, urinary, and total manure N excretion; and (3) to develop robust and reliable N excretion prediction models based on individual data from lactating dairy cows consuming various diets. A raw data set was created based on 5,483 individual cow observations, with 5,420 fecal N excretion and 3,621 urine N excretion measurements collected from 162 in vivo experiments conducted by 22 research institutes mostly located in Europe (n = 14) and North America (n = 5). A sequential approach was taken in developing models with increasing complexity by incrementally adding variables that had a significant individual effect on fecal, urinary, or total manure N excretion. Nitrogen excretion was predicted by fitting linear mixed models including experiment as a random effect. Simple models requiring dry matter intake (DMI) or N intake performed better for predicting fecal N excretion than simple models using diet nutrient composition or milk performance parameters. Simple models based on N intake performed better for urinary and total manure N excretion than those based on DMI, but simple models using milk urea N (MUN) and N intake performed even better for urinary N excretion. The full model predicting fecal N excretion had similar performance to simple models based on DMI but included several independent variables (DMI, diet crude protein content, diet neutral detergent fiber content, milk protein), depending on the location, and had root mean square prediction errors as a fraction of the observed mean values of 19.1% for intercontinental, 19.8% for European, and 17.7% for North American data sets. Complex total manure N excretion models based on N intake and MUN led to prediction errors of about 13.0% to 14.0%, which were comparable to models based on N intake alone. Intercepts and slopes of variables in optimal prediction equations developed on intercontinental, European, and North American bases differed from each other, and therefore region-specific models are preferred to predict N excretion. In conclusion, region-specific models that include information on DMI or N intake and MUN are required for good prediction of fecal, urinary, and total manure N excretion. In absence of intake data, region-specific complex equations using easily and routinely measured variables to predict fecal, urinary, or total manure N excretion may be used, but these equations have lower performance than equations based on intake.
Collapse
Affiliation(s)
- A Bougouin
- Department of Animal Science, University of California, Davis 95616.
| | - A Hristov
- Department of Animal Science, The Pennsylvania State University, University Park 16803
| | - J Dijkstra
- Animal Nutrition Group, Wageningen University and Research, 6700 AH Wageningen, the Netherlands
| | - M J Aguerre
- Department of Animal and Veterinary Sciences, Clemson University, Clemson, SC 29634
| | - S Ahvenjärvi
- Animal Nutrition, Production Systems, Natural Resources Institute Finland (Luke), FI-31600 Jokioinen, Finland
| | - C Arndt
- Mazingira Centre, International Livestock Research Institute (ILRI), 00100 Nairobi, Kenya
| | - A Bannink
- Wageningen Livestock Research, Wageningen University and Research, 6700 AH Wageningen, the Netherlands
| | - A R Bayat
- Animal Nutrition, Production Systems, Natural Resources Institute Finland (Luke), FI-31600 Jokioinen, Finland
| | - C Benchaar
- Sherbrooke Research and Development Centre, Agriculture and Agri-Food Canada, Sherbrooke, Quebec, Canada J1M 0C8
| | - T Boland
- School of Agriculture and Food Science, University College Dublin, Belfield, Dublin 4, Ireland
| | - W E Brown
- Department of Animal and Dairy Sciences, University of Wisconsin-Madison 53706-1205; Department of Animal Sciences, The Ohio State University, Columbus 43210
| | - L A Crompton
- School of Agriculture, Policy and Development, University of Reading, Reading RG6 6AR, United Kingdom
| | - F Dehareng
- Department of Valorisation of Agricultural Products, Walloon Agricultural Research Centre, 5030 Gembloux, Belgium
| | - I Dufrasne
- Department of Veterinary Management of Animal Resources, Faculty of Veterinary Medicine, Fundamental and Applied Research for Animal and Health (FARAH), University of Liège, 4000 Liège, Belgium
| | - M Eugène
- INRAE - Université Clermont Auvergne - VetAgroSup UMR 1213 Unité Mixte de Recherche sur les Herbivores, Centre de recherche Auvergne-Rhône-Alpes, Theix, 63122 Saint-Genès-Champanelle, France
| | - E Froidmont
- Department of Valorisation of Agricultural Products, Walloon Agricultural Research Centre, 5030 Gembloux, Belgium
| | - S van Gastelen
- Wageningen Livestock Research, Wageningen University and Research, 6700 AH Wageningen, the Netherlands
| | - P C Garnsworthy
- School of Biosciences, University of Nottingham, Loughborough LE12 5RD, United Kingdom
| | - A Halmemies-Beauchet-Filleau
- Faculty of Agriculture and Forestry, Department of Agricultural Sciences, University of Helsinki, 00014 Helsinki, Finland
| | - S Herremans
- Department of Valorisation of Agricultural Products, Walloon Agricultural Research Centre, 5030 Gembloux, Belgium
| | - P Huhtanen
- Department of Agricultural Science for Northern Sweden, Swedish University of Agricultural Sciences, SE-901 83, Umeå, Sweden
| | - M Johansen
- Department of Animal Science, Aarhus University, AU Foulum, Dk-8830 Tjele, Denmark
| | - A Kidane
- Department of Animal and Aquacultural Sciences, Norwegian University of Life Sciences, 1433 Ås, Norway
| | - M Kreuzer
- Institute of Agricultural Sciences, ETH Zurich, 8092 Zurich, Switzerland
| | - B Kuhla
- Institute for Farm Animal Biology (FBN), Institute of Nutritional Physiology "Oskar Kellner," Dummerstorf, Mecklenburg-Vorpommern, Germany
| | - F Lessire
- Department of Veterinary Management of Animal Resources, Faculty of Veterinary Medicine, Fundamental and Applied Research for Animal and Health (FARAH), University of Liège, 4000 Liège, Belgium
| | - P Lund
- Department of Animal Science, Aarhus University, AU Foulum, Dk-8830 Tjele, Denmark
| | - E M K Minnée
- DairyNZ Ltd., Private Bag 3221, Hamilton, New Zealand 3240
| | - C Muñoz
- Instituto de Investigaciones Agropecuarias, INIA Remehue, Ruta 5 S, Osorno, Chile
| | - M Niu
- Department of Animal Science, University of California, Davis 95616; Institute of Agricultural Sciences, ETH Zurich, 8092 Zurich, Switzerland
| | - P Nozière
- INRAE - Université Clermont Auvergne - VetAgroSup UMR 1213 Unité Mixte de Recherche sur les Herbivores, Centre de recherche Auvergne-Rhône-Alpes, Theix, 63122 Saint-Genès-Champanelle, France
| | - D Pacheco
- Ag Research, Palmerston North 4410, New Zealand
| | - E Prestløkken
- Department of Animal and Aquacultural Sciences, Norwegian University of Life Sciences, 1433 Ås, Norway
| | - C K Reynolds
- School of Agriculture, Policy and Development, University of Reading, Reading RG6 6AR, United Kingdom
| | - A Schwarm
- Department of Animal and Aquacultural Sciences, Norwegian University of Life Sciences, 1433 Ås, Norway
| | - J W Spek
- Wageningen Livestock Research, Wageningen University and Research, 6700 AH Wageningen, the Netherlands
| | - M Terranova
- AgroVet-Strickhof, ETH Zurich, 8315 Lindau, Switzerland
| | - A Vanhatalo
- Faculty of Agriculture and Forestry, Department of Agricultural Sciences, University of Helsinki, 00014 Helsinki, Finland
| | - M A Wattiaux
- Department of Animal and Dairy Sciences, University of Wisconsin-Madison 53706-1205
| | - M R Weisbjerg
- Department of Animal Science, Aarhus University, AU Foulum, Dk-8830 Tjele, Denmark
| | - D R Yáñez-Ruiz
- Estación Experimental del Zaidin, CSIC, 1, 18008 Granada, Spain
| | - Z Yu
- Department of Animal Sciences, The Ohio State University, Columbus 43210
| | - E Kebreab
- Department of Animal Science, University of California, Davis 95616
| |
Collapse
|
6
|
Quintero-González DC, Sanchez-Bautista J, Agudelo C, Vanegas-García AL, Muñoz C, Santamaria-Alza Y, Cardona - Cardona A, Muñoz M, Vásquez G, González LA. AB0560 CLINICAL, SEROLOGICAL AND IMAGING CHARACTERISTICS OF LATIN AMERICAN PATIENTS WITH LUPUS MYOCARDITIS: A CASE-CONTROL STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundLupus myocarditis (LM) is an uncommon manifestation of systemic lupus erythematosus (SLE),with a prevalence of 9% that tends to be lower in recent studies; it can range from subclinical to life-threatening manifestations (1). The clinical and immunological characteristics of LM have not been established in Latin American patients.ObjectivesTo determine the clinical, serological, and imaging characteristics of patients with LM.MethodsWe conducted a single-center, case-control study that enrolled hospitalized patients between 2012 and 2020 in Colombia. Fifteen LM patients (cases) were matched by age and sex with thirty non-LM patients (controls). Descriptive, comparative, and logistic regression analyses were performed.ResultsPatients with LM were mostly females (93.3%) with a mean age of 28.2 years. The major affected clinical domains associated was renal (80%). Myocardial involvement occurred after SLE diagnosis with a mean of 5.1 years. Dyspnea (73.3%) was the main clinical manifestation. Troponin was high in 92.3% and echocardiographic findings included decreased left ventricular ejection fraction (LVEF) in the 60% of cases (mean 40%), diastolic dysfunction (61.5%), left ventricular dilatation (53.3%) and global hypokinesia 35.7%. The most common valvulopathy was mild mitral regurgitation. Nine LM patients underwent cardiac magnetic resonance. In this modality, mean LVEF was 38%, increased regional intensity on T2-weighted images, increased myocardial potentiation ratio on T1, and non-ischemic enhancement (mainly epicardial) was presented on 85.7%, 60%, and 57.1%, respectively. All patients received glucocorticoids and cyclophosphamide. Comparisons of the demographic, clinical, serological between LM and non-LM groups are shown in Table 1.Table 1.Demographic, clinical and serological characteristics.VariableLM (n=15)Non-LMP-valueFemale93.3%100%0.333Age SLE24.9 (SD 12)28.3 (SD 13.9)0.515Clinical domainsCutaneous46.7%90%0.003Articular60%76.7%0.245Hematological60%83.3%0.086Serosal53.3%36.7%0.227Renal80%76.7%0.560Neuropsyquiatric6.7%26.7%0.115Vascular13.3%50%0.017PCR mg/dL10.1 (SD 9.3)2.8 (SD 4.6)0.0004Erythrocyte sedimentation rate mm/H52.9 (SD 25.7)43.9 (SD 32.9)0.267Creatinine mg/dL1.4 (SD 0.9)1.9 (SD 2.5)0.294C3 mg/dL57.4 (SD 22.4)86.2 (SD 29.9)0.002C4 mg/dL9.6 (SD 8.3)16.4 (SD 9.3)0.009Anti-dsDNA86.7%52.4%0.034SLEDAI score14.7 (SD 5.7)6.8 (SD 7.6)0.0003SD: Standard deviationBivariate logistic regression showed that LM was independently associated with anti-dsDNA (OR 1.17, IC 1.04 – 1.31, p= 0.004), higher SLEDAI score (OR 1.17, IC 1.04 – 1.31, p=0,006), higher RCP (OR 1.21, IC 1.04 – 1.4, p=0.013), lower C3 (OR 0.96, IC 0.93 – 0.98, p:0,06) and lower C4 (OR 0.90 IC 0.82 – 0.99 P=0,036), highlighting its relationship with disease activity.ConclusionLM is a potentially severe manifestation and occurs in patients with higher disease activity, as was evidenced in the present study by low complement, anti-dsDNA and SLEDAI score. In the proper clinical context, noninvasive diagnostic tests should detect myocardial involvement in SLE.References[1]du Toit, Riette et al. “Outcome of clinical and subclinical myocardial injury in systemic lupus erythematosus - A prospective cohort study.” Lupus vol. 30,2 (2021): 256-268. doi:10.1177/0961203320976960Disclosure of InterestsNone declared
Collapse
|
7
|
Quintero-González DC, Muñoz-Urbano M, Sanchez-Bautista J, Santamaria-Alza Y, Ramírez A, Muñoz C, Vanegas-García AL, Vásquez G, González LA. AB0527 DIFFUSE ALVEOLAR HEMORRHAGE IN LATIN AMERICAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE-CONTROL STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundDiffuse alveolar hemorrhage (DAH) is an uncommon and life-threatening complication of systemic lupus erythematosus (SLE) with a high mortality rate (estimated average 50%). The presence of respiratory symptoms (dyspnea, cough, hemoptysis), a new drop in hemoglobin levels, and diffuse infiltrates on chest imaging should raise suspicion of this complication.ObjectivesWe aimed to describe DAH-SLE patients and compare them with non-DAH SLE patients.MethodsWe conducted a single-center, case-control study that enrolled hospitalized patients between 2012 and 2020 in Colombia. Twenty-three DAH-SLE patients (cases) were matched by age and sex with 23 non-DAH-SLE patients (controls). Descriptive, comparative, and logistic regression analyses were performed.ResultsIn seven (30.4%) patients, DAH was the initial manifestation of SLE; 69.5% of DAH-SLE patients were females with a mean age of 35 years. Lupus nephritis was present in 65% of cases, mean hemoglobin decrease was 2.22 g/l [standard deviation (SD) 0.92 g/L], and 78% had hemosiderophages in bronchoalveolar lavage. All patients received intravenous (IV) pulses of methylprednisolone followed by high-dose steroids, 87.0% IV cyclophosphamide pulses, 60.8% plasmapheresis, 21.7% IV immunoglobulin, and 8.7% rituximab. Comparisons between DAH and non-DAH groups are shown in Table 1. Bivariate logistic regression analysis showed that male sex (OR 9.625 CI95% 1.07 - 86.17; p=0.043), higher SLEDAI-2K score (OR 1. 28 CI95% 1.10 - 1.48; p=0.001), and higher C-reactive protein (CRP) levels (OR 1.09 CI95% 1.01 - 1.18; p=0.016) were independently associated with the occurrence of DAH, whereas prior use of corticosteroids (OR 0.029 CI95% 0.003 - 0.25; p=0.001) and antimalarials (OR 0.121 CI95% 0.03 - 0.45; p=0.002), higher hemoglobin levels (OR 0.457 CI95% 0.29 - 0.71; p=0.001), higher C3 (OR 0.94 CI95% 0.91 - 0.97; p<0.0001) and higher C4 levels (OR 0.87 CI95% 0.80 - 0.95; p=0.002) were negatively associated with DAH occurrence (Graph).Table 1.Demographic, clinical, serological, and therapeutic characteristics in DAH-SLE patients and non-DAH-SLE patientsVariableNon-DHA SLE (n = 23)DHA SLE (n = 23)Female95.6%69.5%Age (years)27.9 (SD 12.8)34.82 (SD 17.3)Hospital stay (days)*20.7 (SD 29.1)34.39 (24.4)SLEDAI-2K*6.17 (SD 5.9)21.77 (12.5)Creatinine (mg/dL)*2.5 (SD 3.7)4.23 (SD 5.2)Leucocyte (cell/mm3)8907 (5668)9408 (5477)Neutrophil (cell/mm3)7112 (5595)8063 (5456)Lymphocyte (cell/mm3)1236 (759)952 (425)Hemoglobin (g/L)10.5 (2.6)6.9 (1.5)Ureic nitrogen (mg/dL)*33.79 (SD 28.87)45.73 (SD 25.64)ESR (mm/Hour)51.5 (35.72)64.65 (47.50)CPR (mg/dL)*5.21 (SD 8.16)12.42 (9.63)Ferritina (ng/mL)509 (526)891 (856)Lactate dehydrogenase (U/L)*314 (SD 114)503 (SD 357)C3 (mg/dL)*84.8 (SD 23.07)44.84 (SD 27.91)C4 (mg/dL)*20.5 (10.3)9.5 (8.2)Anti-dsDNA42.8%71.4%Anti-Ro38.8%38.8%Anti-La11.1%10.5%Anti-RNP44.4%47.3%Anti- Sm38.8%35%IgG ACL09%IgM ACL10.5%13.6%Lupus anticoagulant33.3%33.33%Mucocutaneous involvement78.2%69.5%Articular involvement73.9%60.8%Hematological involvement86.9%69.5%Renal involvement91.3%86.9%Serosal involvement34.7%26.1%Prior glucocorticoid*95.6%39.1%Prior antimalarial*69.5%21.7%Dead4.3%21.7%*P value < 0.05ConclusionIn about one-third of patients diagnosed with DAH, this life-threatening complication was the initial presentation of SLE. Male sex, higher SLEDAI-2K scores, and higher CRP levels were associated with DAH occurrence, whereas higher hemoglobin levels, elevated complement levels, prior use of glucocorticoids, and antimalarial treatment were negatively associated with the occurrence of DAH.Figure 1.Forest plot of factors associated with DHA-SLE patients. **The Forest plot graph does not include the male sex variable due to its wide confidence intervals.Disclosure of InterestsNone declared
Collapse
|
8
|
Muñoz C, Gonzálvez M, Buendía A, Lara L, Escribano F, Martínez-Carrasco C. First report of a hawfinch (Coccothraustes coccothraustes) parasitized by Harpirhynchus nidulans in the Iberian Peninsula. Parasitol Int 2022; 88:102552. [DOI: 10.1016/j.parint.2022.102552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2021] [Revised: 01/14/2022] [Accepted: 01/24/2022] [Indexed: 11/28/2022]
|
9
|
Muñoz C, Pérez-Cutillas P, Berriatua E, Ortiz J. On how trap positioning affects phlebotomine sand fly density estimations. Med Vet Entomol 2021; 35:490-494. [PMID: 33320358 DOI: 10.1111/mve.12501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 11/24/2020] [Accepted: 11/25/2020] [Indexed: 06/12/2023]
Abstract
There is a need for standardizing sand fly sampling methodology and guidance on trap positioning for quantitative sand fly studies. We investigated differences in sand fly density with 'sticky' interception and CO2 -light attraction traps, in relation to trap distance to the ground and the presence or absence of a continuous or discontinuous (wire mesh) vertical surface adjacent to the trap. The study, conducted in a dog kennel in southeast Spain, lasted 48 days and collected 692 Phlebotomus papatasi, P. perniciosus, P. ariasi and Sergentomyia minuta specimens. There were no significant differences between species with respect to trap position. Overall, density in sticky traps was highest closest to the ground and next to the continuous vertical surface, followed sequentially by traps similarly placed adjacent to the wire mesh and those hanging from a rope across the kennel yard. In contrast, density in CO2 -light traps was highest in traps hanging from the rope near the ground, followed by those next to the continuous vertical surface. The overall negative relationship between sand fly density and ground distance was not significant for CO2 -light traps next to the continuous vertical surface. Modelling also suggested that sand flies do not use the wire mesh to move vertically.
Collapse
Affiliation(s)
- C Muñoz
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence 'Campus Mare Nostrum', Universidad de Murcia, Murcia, Spain
| | | | - E Berriatua
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence 'Campus Mare Nostrum', Universidad de Murcia, Murcia, Spain
| | - J Ortiz
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence 'Campus Mare Nostrum', Universidad de Murcia, Murcia, Spain
| |
Collapse
|
10
|
Bastos‐Oreiro M, Bailén R, Silva P, Monsalvo S, Pérez Corral A, Carbonell D, Díaz Crespo F, Gómez‐Fernández I, Oarbeascoa G, Dorado N, Muñoz C, Sabell S, Menarguez J, Martínez‐Laperche C, Buño I, Anguita Velasco J, Díez‐Martín JL, Kwon M. RELAPSE CHARACTERIZATION IN DIFFUSE LARGE B CELL LYMPHOMA PATIENTS UNDERGOING COMMERCIAL CAR‐T CELL THERAPY: EXPERIENCE FROM A SINGLE CENTRE. Hematol Oncol 2021. [DOI: 10.1002/hon.180_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M. Bastos‐Oreiro
- Hospital Universitario Gregorio Marañón, *equal contribution Hematology Madrid Spain
| | - R. Bailén
- Hospital Universitario Gregorio Marañón, *equal contribution Hematology Madrid Spain
| | - P. Silva
- Hospital Universitario Gregorio Marañón Hematology Madrid Spain
| | - S. Monsalvo
- Hospital Universitario Gregorio Marañón Hematology Madrid Spain
| | - A. Pérez Corral
- Hospital Universitario Gregorio Marañón Hematology Madrid Spain
| | - D. Carbonell
- Hospital Universitario Gregorio Marañón Hematology Madrid Spain
| | - F. Díaz Crespo
- Hospital Universitario Gregorio Marañón Pathology Madrid Spain
| | | | - G. Oarbeascoa
- Hospital Universitario Gregorio Marañón Hematology Madrid Spain
| | - N. Dorado
- Hospital Universitario Gregorio Marañón Hematology Madrid Spain
| | - C. Muñoz
- Hospital Universitario Gregorio Marañón Hematology Madrid Spain
| | - S. Sabell
- Hospital Universitario Gregorio Marañón Hematology Madrid Spain
| | - J. Menarguez
- Hospital Universitario Gregorio Marañón Pathology Madrid Spain
| | | | - I. Buño
- Hospital Universitario Gregorio Marañón Hematology Madrid Spain
| | | | | | - M. Kwon
- Hospital Universitario Gregorio Marañón Hematology Madrid Spain
| |
Collapse
|
11
|
Sanchez-Bautista J, Santamaria-Alza Y, Quintero C, Muñoz M, Ramírez A, Muñoz C, Vanegas-García AL, Vásquez G, González LA. POS0770 DIFFERENTIAL CLINICAL PRESENTATION BETWEEN SLE RUPHUS PATIENTS AND SLE NON-RHUPUS PATIENTS: A CASE-CONTROL STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Rhupus is a term that describe the coexistence of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Rhupus patients have symmetrical, erosive arthritis, characteristic SLE manifestations and an array of autoantibodies including rheumatoid factor (RF), anti-cyclic citrullinated peptides (anti-CCP), anti-dsDNA, and anti-Sm.1 Joint involvement is common in SLE patients (90%), but only 1% to 9,7% have rhupus.2 Due to its low prevalence, there is still a lack of evidence on its presentation and differences with other SLE patients without rhupus.Objectives:To examine the rhupus prevalence and to compare the clinical and serological characteristics between rhupus, and non-rhupus SLE patients (SLE with arthritis (SLEa), and SLE without arthritis (SLEwa)).Methods:We performed a case-control study. Rhupus patients (cases) were matched 1:1 with non-rhupus SLE patients (controls). Descriptive statistics were calculated and rhupus, SLEa, and SLEwa were compared.Results:A total of 72 patients were included, 24 patients in each group; most were female (87.5%). The median age at rhupus onset was 36.5 years (IQR 30-42.5). RA preceded rhupus in half of the patients, 29% were initially diagnosed as SLE, and 21% were initially diagnosed as rhupus. The median duration of RA was 66 months (IQR 30-144).In the descriptive analysis of rhupus patients, the most affected joints were the proximal interphalangeal and metacarpophalangeal joints (87.5%), followed by the wrists (79.1%). Regarding immunological findings, RF and anti-CCP were positive in 87.5% and 50% of the patients, respectively. As to radiographic findings, the median number of erosions in the hands and wrists was 2 (IQR 0-5) and the median number of joints with narrowed joint space was 7 (IQR: 1.5 - 13.5). In terms of treatment, 95.8% received corticosteroids (median 10 mg/day), 91.6% antimalarials, 79.1% methotrexate, 41.6% leflunomide, and 25.0% rituximab.Patients with rhupus were older and had less renal and hematological involvement than patients with SLEa and SLEwa. SLEa patients had higher seropositivity for anti-RNP and anti-Sm, higher neurological involvement, and higher SLEDAI-2K scores than rhupus patients. Comparisons of other clinical and serological variables between SLE rhupus and non-ruphus patients are shown in table 1 and figure 1.Table 1.Clinical and serological manifestations in rhupus, articular SLE, and non-articular SLEVariablesRHUPUSM (IQR)SLE with arthritisM (IQR)SLE without arthritisM (IQR)P value RHUPUS vs. SLE with arthritisp value RHUPUSvs. SLE without arthritisAge (years) M (IQR)40 (31.5 – 49)29 (21.5 – 45)33 (19.5 – 37.5)0.0430.013CPR M (IQR)2.3 (1– 8.5)1.6 (0.3– 3.6)0.9 (0.2– 2.5)0.3370.032Positive anti-RNP N (%)7 (29.1%)14 (58.3%)7 (29.1%)0.0421.000Positive anti-Sm N (%)5 (20.8%)15 (62.5%)6 (25%)0.0030.500SLEDAI – 2K score M (IQR)4.5 (1 – 7)9 (2 – 18)7 (3.5 – 15)0.0450.082Figure 1.Differences in the frequencies of organic alterations. w/o: without.Conclusion:Patients with rhupus were older and had lower SLEDAI-2K scores compared with those non-rhupus. Furthermore, renal, neurological, and hematological manifestations were more common in non-rhupus patients than in rhupus patients.References:[1]Antonini L, et al. Rhupus: a systematic literature review. Autoimmun Rev. 2020;19(9):102612.[2]Tani C, et al. Rhupus syndrome: Assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. Autoimmun Rev. 2013; 12:537–41.Disclosure of Interests:None declared
Collapse
|
12
|
Urrego Callejas T, Álvarez D, Jaramillo Arroyave D, Vanegas-García AL, Muñoz C. AB0374 CHARACTERISTICS OF A GIANT CELL ARTERITIS COHORT IN LATINOAMERICA. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Giant cell arteritis (GCA) is a large vessel vasculitis (LVV) that affects mostly the elderly (1). Temporal artery biopsy (TAB) has been defined as the gold standard, although this has come to question (3). EULAR guidelines recommended non-invasive imaging techniques such as the temporal artery Doppler ultrasound to aid in LVV diagnosis (2). The characterization of GCA in Latin American countries, and specifically in Colombia, is scarce.Objectives:To perform a clinical, demographical, histopathological, and radiological characterization ofColombian GCA patients.Methods:Retrospective data from GCA patients at two teaching hospitals in Medellín, Colombia, was collected. A bioethics committee previously approved the research protocol. Inclusion criteria: diagnosis of GCA, based on clinical characteristics or imaging/biopsy findings. Exclusion criteria: HIV diagnosis, paraneoplastic large vessel vasculitis. Clinical, radiological, and histopathological variables were selected based on the clinicians’ expertise and the 2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis (3). The data were analyzed in SPSS v22.0 (IBM, USA).Results:Twenty-two patients were collected. Demographical and clinical characteristics are summarized in Table 1. Most patients were women (68.1%), with a mean age of 71.8 years, mean duration of symptoms of 5.3 months. In the cranial form of the disease, the most common symptoms were headache and jaw claudication (95% and 68%). Six patients experienced visual loss: complete unilateral visual loss in two, partial unilateral in two, complete bilateral in one, and partial bilateral in one patient.Sixteen patients (72.7%) underwent TAB; the most common finding was mononuclear infiltrate and internal elastic fragmentation in 43.7% of the biopsies. Giant cells were observed in 6 biopsies (37.5%). Doppler ultrasound was performed in 19 patients (86.35%), finding intima-media thickening and the halo sign t in 7 patients (36.8%).Table 1.Demographical and clinical characteristicsCharacteristicn = 22Mean age (years SD)71.8 (10.6)Female sex n (%)15 (68.1%)Mean symptoms duration (months ± SD)5.3 ± 6.8Mestizo n (%)20 (90%)Headache n (%)21 (95.4%)Jaw claudication n (%)15 (68.1%)Weight loss n (%)13 (59%)Scalp sensitivity n (%)11 (50%)Fever n (%)8 (36.3%)Presence of polymyalgia rheumatica n (%)7 (31.8%)Visual loss n (%)6 (27.2%)Amaurosis fugax n (%)1 (4.5%)Glucocorticoids n (%)22 (100%)Pulse n (%)8 (36.3%)Mean dose (mg ± SD)47.1 ± 16.7Methotrexate n (%)17 (77.7%)Azathioprine n (%)2 (9%)Tocilizumab n (%)1 (4.5%)Conclusion:In this GCA cohort, the main phenotype was cranial GCA, with 95% of the patients presenting with headache. The most common imaging study performed was Doppler ultrasound of temporal arteries, with intima-media thickening and halo sign being the most common findings. The mainstay of treatment was glucocorticoids with methotrexate as a sparing agent. To our knowledge, this study is the first to perform a specific characterization of GCA patients in the Colombian population, and it can represent the foundation of further research for these patients.References:[1]Lazarewicz K, Watson P. Giant cell arteritis. BMJ. 2019 May 30;365:l1964.[2]Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018 May;77(5):636–43.[3]Ehlers L, Askling J, Bijlsma HWJ, Cid MC, Cutolo M, Dasgupta B, et al. 2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. Ann Rheum Dis. 2019;78(9):1160–6.Disclosure of Interests:None declared
Collapse
|
13
|
Casco N, Jorge AL, Palmero D, Alffenaar JW, Fox G, Ezz W, Cho JG, Skrahina A, Solodovnikova V, Bachez P, Arbex MA, Galvão T, Rabahi M, Pereira GR, Sales R, Silva DR, Saffie MM, Miranda RC, Cancino V, Carbonell M, Cisterna C, Concha C, Cruz A, Salinas NE, Revillot ME, Farias J, Fernandez I, Flores X, Gallegos P, Garavagno A, Guajardo C, Bahamondes MH, Merino LM, Muñoz E, Muñoz C, Navarro I, Navarro J, Ortega C, Palma S, Pardenas AM, Pereira G, Castillo PP, Pinto M, Pizarro R, Rivas F, Rodriguez P, Sánchez C, Serrano A, Soto A, Taiba C, Venegas M, Vergara MS, Vilca E, Villalon C, Yucra E, Li Y, Cruz A, Guelvez B, Plaza R, Tello K, Andréjak C, Blanc FX, Dourmane S, Froissart A, Izadifar A, Rivière F, Schlemmer F, Gupta N, Ish P, Mishra G, Sharma S, Singla R, Udwadia ZF, Manika K, Diallo BD, Hassane-Harouna S, Artiles N, Mejia LA, Alladio F, Calcagno A, Centis R, Codecasa LR, D Ambrosio L, Formenti B, Gaviraghi A, Giacomet V, Goletti D, Gualano G, Kuksa L, Danila E, Diktanas S, Miliauskas S, Ridaura RL, López F, Torrico MM, Rendon A, Akkerman OW, Piubello A, Souleymane MB, Aizpurua E, Gonzales R, Jurado J, Loban A, Aguirre S, de Egea V, Irala S, Medina A, Sequera G, Sosa N, Vázquez F, Manga S, Villanueva R, Araujo D, Duarte R, Marques TS, Grecu VI, Socaci A, Barkanova O, Bogorodskaya M, Borisov S, Mariandyshev A, Kaluzhenina A, Stosic M, Beh D, Ng D, Ong C, Solovic I, Dheda D, Gina P, Caminero JA, Cardoso-Landivar J, de Souza Galvão ML, Dominguez-Castellano A, García-García JM, Pinargote IM, Fernandez SQ, Sánchez-Montalvá A, Huguet ET, Murguiondo MZ, Bruchfeld J, Bart PA, Mazza-Stalder J, Tiberi S, Arrieta F, Heysell S, Logsdon J, Young L. TB and COVID-19 co-infection: rationale and aims of a global study. Int J Tuberc Lung Dis 2021; 25:78-80. [PMID: 33384052 DOI: 10.5588/ijtld.20.0786] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
| | | | | | | | - G Fox
- New South Wales, Australia
| | - W Ezz
- New South Wales, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Peinado P, Sanz Garcia E, Moreno I, Dorta M, Alvarez B, Alvarez Gallego R, Madurga R, Ugidos L, Rodriguez Pascual J, Muñoz C, Garcia-Rico E, Cubillo A. 1760P COVID-19 severe pneumonia in cancer patients: Impact and predictive factors. Ann Oncol 2020. [PMCID: PMC7506389 DOI: 10.1016/j.annonc.2020.08.1824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
|
15
|
Abras A, Ballart C, Fernández-Arévalo A, Llovet T, Gállego M, Muñoz C. ARCHITECT Chagas® as a single test candidate for Chagas disease diagnosis: evaluation of two algorithms implemented in a non-endemic setting (Barcelona, Spain). Clin Microbiol Infect 2020; 27:S1198-743X(20)30385-2. [PMID: 32653657 DOI: 10.1016/j.cmi.2020.07.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Revised: 06/27/2020] [Accepted: 07/01/2020] [Indexed: 12/01/2022]
Abstract
OBJECTIVES To evaluate two algorithms for the diagnosis of chronic and congenital Chagas disease (CD), both including the chemiluminescent microparticle immunoassay ARCHITECT Chagas® (CMIA) as a single test but with an amended signal-to-cut-off ratio (S/CO) of ≥6, instead of an S/CO of ≥1 as indicated by the manufacturer. METHODS The study encompassed two panels of retrospective samples: 831 sera from 786 adolescents and adults (panel A), and 96 sera from 35 newborn infants with CD-infected mothers (panel B). A CMIA-negative result was deemed conclusive, whereas samples with an S/CO ≥ 0.8 were confirmed by a second test (BioELISA Chagas, ELISAr). RESULTS In panel A, seropositivity was 13% (102/786); 10 samples gave discordant results for CMIA and ELISAr, all of which were CMIA positive and had CD confirmed through a previous diagnosis by two positive serological tests. In panel B, all newborns were considered non-infected based on both a progressive decrease in antibody titres over time and negative real-time PCR results. CMIA still gave positive results in two infants aged 10 months but no S/CO values ≥6 were observed from 4 months on. CONCLUSIONS CMIA is a firm candidate for use as a single CD diagnostic test in non-endemic countries. The algorithm with the ≥6 S/CO is as an efficient method for chronic CD diagnosis. CMIA could also be used as a single test to screen infants for congenital infection at the age of 10 months or even earlier if applying the corrected cut-off ratio, although further studies are required.
Collapse
Affiliation(s)
- A Abras
- Laboratori d'Ictiologia Genètica, Departament de Biologia, Universitat de Girona, Girona, Spain
| | - C Ballart
- Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
| | - A Fernández-Arévalo
- Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain; Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Institut de Recerca Biomèdica Sant Pau, Barcelona, Spain
| | - T Llovet
- Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, Spain
| | - M Gállego
- Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
| | - C Muñoz
- Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Institut de Recerca Biomèdica Sant Pau, Barcelona, Spain; Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, Spain.
| |
Collapse
|
16
|
Luque L, Rodrigo T, García-García JM, Casals M, Millet JP, Caylà J, Orcau A, Agüero R, Alcázar J, Altet N, Altube L, Álvarez F, Anibarro L, Barrón M, Bermúdez P, Bikuña E, Blanquer R, Borderías L, Bustamante A, Calpe J, Caminero J, Cañas F, Casas F, Casas X, Cases E, Castejón N, Castrodeza R, Cebrián J, Cervera A, Ciruelos J, Delgado A, De Souza M, Díaz D, Domínguez M, Fernández B, Gallardo J, Gallego M, Clemente MG, García C, García F, Garros F, Gort A, Guerediaga A, Gullón J, Hidalgo C, Iglesias M, Jiménez G, Jiménez M, Kindelan J, Laparra J, López I, Lera R, Lloret T, Marín M, Lacasa XM, Martínez E, Martínez A, Medina J, Melero C, Milà C, Millet J, Mir I, Molina F, Morales C, Morales M, Moreno A, Moreno V, Muñoz A, Muñoz C, Muñoz J, Muñoz L, Oribe M, Parra I, Penas A, Pérez J, Rivas P, Rodríguez J, Ruiz-Manzano J, Sala J, Sandel D, Sánchez M, Sánchez M, Sánchez P, Santamaría I, Sanz F, Serrano A, Somoza M, Tabernero E, Trujillo E, Valencia E, Valiño P, Vargas A, Vidal I, Vidal R, Villanueva M, Villar A, Vizcaya M, Zabaleta M, Zubillaga G. Factors Associated With Extrapulmonary Tuberculosis in Spain and Its Distribution in Immigrant Population. Open Respiratory Archives 2020. [DOI: 10.1016/j.opresp.2020.04.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
|
17
|
Vermeiren P, Muñoz C, Ikejima K. Microplastic identification and quantification from organic rich sediments: A validated laboratory protocol. Environ Pollut 2020; 262:114298. [PMID: 32163807 DOI: 10.1016/j.envpol.2020.114298] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Revised: 02/11/2020] [Accepted: 02/28/2020] [Indexed: 06/10/2023]
Abstract
Plastic pollution presents a global environmental concern with potentially widespread ecological, socio-economic and health implications. Methodological advances in microplastic extraction, quantification and identification from sediments have been made. However, integrating these fragmentary advances into a holistic, cost-effective protocol and applying it to organic rich sediments with fine grain size remains a challenge. Nonetheless, many hot spots of microplastic contamination such as harbour and estuarine sediments are characterised by such sediments. We conducted a series of experiments to integrate methodological advances, and clarify their applicability to organic rich sediments with fine grain size. The resulting protocol consisted of three stages. First, pre-treatment with Fenton's reagent was found to be efficient in reducing organic matter content, compatible with later Fourier Transform-Infrared Spectroscopy (FT-IR) for polymer identification, although it did affect the size of polyethylene (PE) and polyethylene terephthalate (PET). Secondly, a novel density separation column with a top overflow (the OC-T) obtained recovery rates above 90% for microplastics present in a ZnCL2 solution. Finally, automated epifluorescence microscopic image analysis of Nile Red stained filters with selected validation of polymer identities using FT-IR revealed 91.7% of stained particles to be plastics. A case study on estuarine sediments demonstrated a high extraction efficiency with quantification possible down to 125 μm and detection possible down to 62.5 μm. This makes this protocol suitable for large scale monitoring of microplastics in sediments of estuarine origin provided polymer specific recovery rates, background contamination and uncertainty in Nile Red identification is accounted for. Subject to further validation, the protocol could also offer a solution to similar organic rich sediments with fine grain size, such as some soils and sludge, to improve our ability to conduct cost-effective, large scale monitoring of microplastic contamination.
Collapse
Affiliation(s)
- P Vermeiren
- Laboratory for Coastal Ecology and Conservation, Faculty of Agriculture and Marine Science, Kochi University, Japan; Dept. Environmental Science, Faculty of Science, Radboud University, The Netherlands.
| | - C Muñoz
- Laboratory for Coastal Ecology and Conservation, Faculty of Agriculture and Marine Science, Kochi University, Japan; Dept. Environmental Science, Faculty of Science, Radboud University, The Netherlands
| | - K Ikejima
- Laboratory for Coastal Ecology and Conservation, Faculty of Agriculture and Marine Science, Kochi University, Japan
| |
Collapse
|
18
|
Pekolj J, Clariá Sánchez R, Salceda J, Maurette RJ, Schelotto PB, Pierini L, Cánepa E, Moro M, Stork G, Resio N, Neffa J, Mc Cormack L, Quiñonez E, Raffin G, Obeide L, Fernández D, Pfaffen G, Salas C, Linzey M, Schmidt G, Ruiz S, Alvarez F, Buffaliza J, Maroni R, Campi O, Bertona C, de Santibañes M, Mazza O, Belotto de Oliveira M, Diniz AL, Enne de Oliveira M, Machado MA, Kalil AN, Pinto RD, Rezende AP, Ramos EJB, Talvane T Oliveira A, Torres OJM, Jarufe Cassis N, Buckel E, Quevedo Torres R, Chapochnick J, Sanhueza Garcia M, Muñoz C, Castro G, Losada H, Vergara Suárez F, Guevara O, Dávila D, Palacios O, Jimenez A, Poggi L, Torres V, Fonseca GM, Kruger JAP, Coelho FF, Russo L, Herman P. Laparoscopic Liver Resection: A South American Experience with 2887 Cases. World J Surg 2020; 44:3868-3874. [PMID: 32591841 DOI: 10.1007/s00268-020-05646-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND Laparoscopic liver resections (LLR) have been increasingly performed in recent years. Most of the available evidence, however, comes from specialized centers in Asia, Europe and USA. Data from South America are limited and based on single-center experiences. To date, no multicenter studies evaluated the results of LLR in South America. The aim of this study was to evaluate the experience and results with LLR in South American centers. METHODS From February to November 2019, a survey about LLR was conducted in 61 hepatobiliary centers in South America, composed by 20 questions concerning demographic characteristics, surgical data, and perioperative results. RESULTS Fifty-one (83.6%) centers from seven different countries answered the survey. A total of 2887 LLR were performed, as follows: Argentina (928), Brazil (1326), Chile (322), Colombia (210), Paraguay (9), Peru (75), and Uruguay (8). The first program began in 1997; however, the majority (60.7%) started after 2010. The percentage of LLR over open resections was 28.4% (4.4-84%). Of the total, 76.5% were minor hepatectomies and 23.5% major, including 266 right hepatectomies and 343 left hepatectomies. The conversion rate was 9.7%, overall morbidity 13%, and mortality 0.7%. CONCLUSIONS This is the largest study assessing the dissemination and results of LLR in South America. It showed an increasing number of centers performing LLR with the promising perioperative results, aligned with other worldwide excellence centers.
Collapse
Affiliation(s)
- J Pekolj
- HPB Surgery Section, General Surgery Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - R Clariá Sánchez
- HPB Surgery Section, General Surgery Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - J Salceda
- Hospital Ramón Santamarina, Tandil, Argentina
| | | | | | - L Pierini
- Clínica Nefrología, Clínica Uruguay, Hospital Iturraspe, Santa Fe, Argentina
| | - E Cánepa
- Hospital Privado de Comunidad, Mar del Plata, Argentina
| | - M Moro
- Hospital Italiano - Regional Sur, Bahía Blanca, Argentina
| | - G Stork
- Hospital Italiano - Regional Sur, Bahía Blanca, Argentina
| | - N Resio
- Unidad HPB Sur, General Roca, Argentina
| | - J Neffa
- Hospital Italiano de Mendoza, Mendoza, Argentina
| | | | - E Quiñonez
- Hospital El Cruce, Buenos Aires, Argentina
| | - G Raffin
- Hospital Argerich, Buenos Aires, Argentina
| | - L Obeide
- Hospital Universitario Privado, Córdoba, Argentina
| | - D Fernández
- Clínica Pueyrredón, Mar del Plata, Argentina
| | - G Pfaffen
- Sanatorio Güemes, Buenos Aires, Argentina
| | - C Salas
- Sanatorio 9 de Julio, Santiago del Estero, Argentina, Hospital Centro de Salud, San Miguel de Tucumán, Argentina
| | - M Linzey
- Hospital Angel C. Padilla, San Miguel de Tucumán, Argentina
| | - G Schmidt
- Hospital Escuela Gral, Corrientes, Argentina
| | - S Ruiz
- Clínica Colón, Mar del Plata, Argentina
| | - F Alvarez
- Clínica Reina Fabiola, Hospital Italiano, Córdoba, Argentina
| | | | - R Maroni
- Hospital Papa Francisco, Salta, Argentina
| | - O Campi
- Clínica Regional General Pico, Santa Rosa, Argentina
| | - C Bertona
- Hospital Español, Mendoza, Argentina
| | - M de Santibañes
- HPB Surgery Section, General Surgery Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - O Mazza
- HPB Surgery Section, General Surgery Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | | | - A L Diniz
- A.C. Camargo Cancer Center, São Paulo, Brazil
| | | | | | - A N Kalil
- Santa Casa de Porto Alegre, Universidade Federal de Ciências da Saúde, Porto Alegre, Brazil
| | - R D Pinto
- Hospital Santa Catarina de Blumenau, Blumenau, Brazil
| | | | - E J B Ramos
- Hospital Nossa Senhora das Graças, Curitiba, Brazil
| | | | - O J M Torres
- Hospital Universitario HUUFMA, Hospital São Domingos, UDI Hospital, Fortaleza, Brazil
| | | | - E Buckel
- Clínica Las Condes, Santiago, Chile
| | | | | | | | - C Muñoz
- Hospital de Talca, Talca, Chile
| | | | - H Losada
- Hospital de Temuco, Temuco, Chile
| | - F Vergara Suárez
- Clínica Vida - Fundación Colombiana de Cancerología, Medellin, Colombia
| | - O Guevara
- Instituto Nacional de Cancerologia, Bogotá, Colombia
| | | | | | - A Jimenez
- Hospital Clínicas, Asunción, Paraguay
| | - L Poggi
- Clínica Anglo Americana, Lima, Peru
| | - V Torres
- Hospital Guillermo Almenara ESSALUD, Lima, Peru
| | - G M Fonseca
- Hospital das Clínicas - University of São Paulo School of Medicine, São Paulo, Brazil
| | - J A P Kruger
- Hospital das Clínicas - University of São Paulo School of Medicine, São Paulo, Brazil
| | - F F Coelho
- Hospital das Clínicas - University of São Paulo School of Medicine, São Paulo, Brazil
| | - L Russo
- Hospital Maciel, Casmu, Montevideo, Uruguay
| | - P Herman
- Hospital das Clínicas - University of São Paulo School of Medicine, São Paulo, Brazil.
| |
Collapse
|
19
|
Del Alcázar E, Suárez-Pérez JA, Armesto S, Rivera R, Herrera-Acosta E, Herranz P, Martín I, Montesinos E, Hospital M, Vilarrasa E, Ferran M, Ruiz-Villaverde R, Sahuquillo-Torralba A, Ruiz-Genao DP, Pérez-Barrio S, Muñoz C, Llamas M, Valentí F, Mitxelena MJ, López-Ferrer A, Carretero G, Vidal D, Mollet J, Belinchón I, Carrascosa JM. Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. J Eur Acad Dermatol Venereol 2020; 34:2821-2829. [PMID: 32271966 DOI: 10.1111/jdv.16439] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Accepted: 03/16/2020] [Indexed: 01/10/2023]
Abstract
BACKGROUND Little has been published on the real-world effectiveness and safety of apremilast in psoriasis. OBJECTIVES To evaluate the effectiveness, safety and drug survival of apremilast at 52 weeks in patients with moderate to severe plaque psoriasis or palmoplantar psoriasis in routine clinical practice. METHODS Retrospective, multicentre study of adult patients with moderate to severe plaque psoriasis or palmoplantar psoriasis treated with apremilast from March 2016 to March 2018. RESULTS We studied 292 patients with plaque psoriasis and 85 patients with palmoplantar psoriasis. The mean (SD) Psoriasis Area and Severity Index (PASI) score was 10.7 (7.0) at baseline and 3.0 (4.2) at 52 weeks. After 12 months of treatment, 73.6% of patients had a PASI score of 3 or less. In terms of relative improvement by week 52, 49.7% of patients achieved PASI-75 (≥75% reduction in PASI score) and 26.5% achieved PASI-90. The mean physician global assessment score for palmoplantar psoriasis fell from 4.2 (5.2) at baseline to 1.3 (1.3) at week 52. Overall drug survival after 1 year of treatment with apremilast was 54.9 %. The main reasons for treatment discontinuation were loss of efficacy (23.9%) and adverse events (15.9%). Almost half of the patients in our series (47%) experienced at least one adverse event. The most common events were gastrointestinal problems. CONCLUSIONS Apremilast may be a suitable alternative for the treatment of moderate to severe psoriasis and palmoplantar psoriasis. Although the drug has a good safety profile, adverse gastrointestinal effects are common.
Collapse
Affiliation(s)
- E Del Alcázar
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - J A Suárez-Pérez
- Department of Dermatology, Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | - S Armesto
- Department of Dermatology, Hospital Universitario de Valdecilla, Santander, Spain
| | - R Rivera
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - E Herrera-Acosta
- Department of Dermatology, Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | - P Herranz
- Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain
| | - I Martín
- Department of Dermatology, Hospital Universitario Getafe, Madrid, Spain
| | - E Montesinos
- Department of Dermatology, Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - M Hospital
- Department of Dermatology, Hospital Universitario Puerta de Hierro Majadahonda Madrid, Spain
| | - E Vilarrasa
- Department of Dermatology, Hospital Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
| | - M Ferran
- Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions Mèdiques, Barcelona, Spain
| | - R Ruiz-Villaverde
- Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain
| | - A Sahuquillo-Torralba
- Department of Dermatology, Hospital Universitario y Politécnico La Fe - Instituto de Investigación Sanitaria La Fe, Valencia, Spain
| | - D P Ruiz-Genao
- Department of Dermatology, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - S Pérez-Barrio
- Department of Dermatology, Hospital Universitario Basurto, Bilbao, Spain
| | - C Muñoz
- Department of Dermatology, Hospital de Granollers, Granollers, Spain
| | - M Llamas
- Department of Dermatology, Hospital Universitario La Princesa, Madrid, Spain
| | - F Valentí
- Department of Dermatology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - M J Mitxelena
- Department of Dermatology, Hospital Universitario de Navarra, Pamplona, Spain
| | - A López-Ferrer
- Department of Dermatology, Hospital Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
| | - G Carretero
- Department of Dermatology, Hospital Universitario Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain
| | - D Vidal
- Department of Dermatology, Hospital Moisès Broggi, Sant Joan Despí, Spain
| | - J Mollet
- Department of Dermatology, Hospital Universitari Vall d'Hebrón, Barcelona, Spain
| | - I Belinchón
- Department of Dermatology, Hospital Universitario de Alicante -ISABIAL, UMH Alicante, Alicante, Spain
| | - J M Carrascosa
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| |
Collapse
|
20
|
Pérez-Cutillas P, Muñoz C, Martínez-De La Puente J, Figuerola J, Navarro R, Ortuño M, Bernal LJ, Ortiz J, Soriguer RC, Berriatua E. A spatial ecology study in a high-diversity host community to understand blood-feeding behaviour in Phlebotomus sandfly vectors of Leishmania. Med Vet Entomol 2020; 34:164-174. [PMID: 31930740 DOI: 10.1111/mve.12427] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/03/2019] [Revised: 11/02/2019] [Accepted: 12/09/2019] [Indexed: 06/10/2023]
Abstract
Molecular studies indicate that Phlebotomine sandflies (Diptera: Psychodidae) blood feed on many vertebrate species, of which only a few are proven parasite reservoirs. Investigating sandfly vector feeding preferences is therefore important and requires taking into account the availability and accessibility of host species. In terms of the latter, it is necessary to consider the metabolic cost to the insect of reaching the host and moving on to a suitable breeding site. The present study used statistical modelling to compare the feeding patterns of Phlebotomus perniciosus (n = 150), Phlebotomus papatasi (n = 35) and Phlebotomus ariasi (n = 7) on each of an average of 30 host species in a wildlife park in Murcia, Spain. Sandfly feeding movement costs were estimated as a function of the distance and altitude gradients saved by the insect, assuming that they displayed 'site fidelity'. Most (87%) engorged females were caught <100 m from the host on which they had fed. Although the percentage of bloodmeals was highest on fallow deer (Dama dama) (30%) and red deer (Cervus elaphus) (26%), the predicted feeding probability after considering movement cost was highest for red deer and common eland (Taurotragus oryx), and positively associated with host census. These results suggest that, under similar circumstances, sandflies prefer to feed on some host species more than on others.
Collapse
Affiliation(s)
- P Pérez-Cutillas
- Grupo de Erosión y Conservación de Suelos, Centro de Edafología y Biología Aplicada del Segura, Consejo Superior de Investigaciones Científicas (CEBAS-CSIC), Murcia, Spain
- Departamento de Geografía, Universidad de Murcia, Murcia, Spain
| | - C Muñoz
- Departamento de Sanidad Animal, Facultad de Veterinaria, Campus de Excelencia Internacional Regional 'Campus Mare Nostrum', Universidad de Murcia, Murcia, Spain
| | - J Martínez-De La Puente
- Departamentode Etología y Conservación de la Biodiversidad, Estación Biológica de Doñana, Consejo Superior de Investigaciones Científicas (EBD-CSIC), C/ Américo Vespucio, Seville, Spain
- Ciber de Epidemiología y Salud Pública (CIBERESP), Seville, Spain
| | - J Figuerola
- Departamentode Etología y Conservación de la Biodiversidad, Estación Biológica de Doñana, Consejo Superior de Investigaciones Científicas (EBD-CSIC), C/ Américo Vespucio, Seville, Spain
- Ciber de Epidemiología y Salud Pública (CIBERESP), Seville, Spain
| | - R Navarro
- Sección Veterinaria, Parque Zoológico Terra Natura Murcia, C/ Regidor Cayetano Gago, s/n, Murcia, Spain
| | - M Ortuño
- Departamento de Sanidad Animal, Facultad de Veterinaria, Campus de Excelencia Internacional Regional 'Campus Mare Nostrum', Universidad de Murcia, Murcia, Spain
| | - L J Bernal
- Departamento de Medicina y Cirugía Animal, Facultad de Veterinaria, Campus de Excelencia Internacional Regional 'Campus Mare Nostrum', Universidad de Murcia, Murcia, Spain
| | - J Ortiz
- Departamento de Sanidad Animal, Facultad de Veterinaria, Campus de Excelencia Internacional Regional 'Campus Mare Nostrum', Universidad de Murcia, Murcia, Spain
| | - R C Soriguer
- Departamentode Etología y Conservación de la Biodiversidad, Estación Biológica de Doñana, Consejo Superior de Investigaciones Científicas (EBD-CSIC), C/ Américo Vespucio, Seville, Spain
- Ciber de Epidemiología y Salud Pública (CIBERESP), Seville, Spain
| | - E Berriatua
- Departamento de Sanidad Animal, Facultad de Veterinaria, Campus de Excelencia Internacional Regional 'Campus Mare Nostrum', Universidad de Murcia, Murcia, Spain
| |
Collapse
|
21
|
Vanegas A, Torres F, Muñoz C, Jaramillo D, Hernandez L, Vásquez G, Restrepo Escobar M, González LA, Velásquez I. AB0538 PREGNANCY OUTCOMES IN PATIENTS WITH TAKAYASU’S ARTERITIS: CASE SERIES. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Takayasu’s arteritis (TA) is most prevalent in women of childbearing age. Although its activity and risk of relapse are low during pregnancy, up to 40% of patients may have unfavorable obstetric outcomes and therefore it is important to know their clinical behavior.Objectives:To describe the clinical features and obstetric outcomes of pregnant women with TA treated in a tertiary center.Methods:Retrospective evaluation of medical records of 6 pregnancies in 6 women with TAs treated in a tertiary center in Medellin, Colombia between 2011-2018.Results:Six women who were 17.5 (RI 9.25) years old at diagnosis and 24 (RI 8.25) years old at delivery, their disease duration were 5.5 (RI 10.5) years. Three patients had extensive aortic involvement classified as Numano type V, two as type IIB and one as type I. At delivery, three patients were active and required immunosuppressants, five had high blood pressure, one developed preeclampsia in the second trimester, one had severe mitral and tricuspid insufficiency with decreased ejection fraction of the left ventricle; two had aneurysms (left subclavian artery and ascending aorta). There were two fetal deaths, one due to intrauterine growth restriction and placental insufficiency and another of unknown etiology; both patients with disease activity, extensive aortic condition and arterial hypertension; no pregnancy resulted in abortion or preterm birth. Five deliveries were by caesarean section by maternal indication; there was no aortic dissection, aneurismal rupture or cerebral hemorrhage (table).TablePatient’s characteristicsPatientAge at diagnosisAge at deliveryClinical featuresHata-Numano classificationMaternal outcomeFetal outcome1617HT, absence of left brachial and radial pulses, L carotid and subclavian murmurs, LVEF 47%VHT, C-sectionTerm delivery, SGA22226HT, abscence of L brachial and radial pulses, L carotid and subclavian murmurs, dyspnea, anginaV(plus pulmonary)HT, vaginal birthPlacental insufficiency, IUGR, fetal death31438HT, abscence of L brachial and radial pulses, L carotid and subclavian murmurs, intermittent claudication, dyspnea, aortic regurgitationIIBHT, C-sectionTerm delivery, SGA41824HT, malaise,, abscence of L brachial and radial pulses, intermittent claudication, arthralgiaIIBPreeclampsia, C-sectionTerm delivery, SGA51722Fever, malaise, intermittent claudication, arthralgiaIC-sectionTerm delivery, SGA62124HT, abscense of bilateral femoral, popliteal, tibial and pedial pulses, headache, dizziness, amaurosisVHT, C-sectionFetal deathHT: hypertension; L: left; LVEF: left ventricular ejection fraction; C-section: cesarean section; SGA: small for gestational age; IUGR: intrauterine growth restrictionConclusion:Pregnant women with active disease and extensive aortic condition presented unfavorable obstetric results, suggesting that an inadequate control of vasculitis may lead to greater maternal-fetal complications.References:[1]Assad APL, da Silva TF, Bonfa E, Pereira RMR. Maternal and Neonatal Outcomes in 89 Patients with Takayasu Arteritis (TA): Comparison Before and After the TA Diagnosis. J Rheumatol. 2015 Oct;42(10):1861–4.[2]Hidaka N, Yamanaka Y, Fujita Y, Fukushima K, Wake N. Clinical manifestations of pregnancy in patients with Takayasu arteritis: experience from a single tertiary center. Arch Gynecol Obstet. 2012 Feb;285(2):377–85.Disclosure of Interests:None declared
Collapse
|
22
|
Vargas Ruíz RD, Gómez Rosero JA, Muñoz C, Jaramillo Arroyave D, Hernandez L, González LA, Vásquez G, Restrepo Escobar M, Vanegas A. FRI0222 MAGNETIC RESONANCE IMAGING OF MUSCLE INVOLVEMENT IN POLYARTERITIS NODOSA. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.6538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:muscle involvement is frequently reported in polyarteritis nodosa (PAN), mostly as myalgia, muscle swelling, and gait difficulty due to intramuscular arteries involvement, peripheral neuropathy, or myositis with slightly or no elevation of muscle enzymes. Magnetic resonance imaging (MRI) findings of compromised muscles have been reported in isolated cases, mainly as a limited form of PAN, however, muscular involvement patterns in MRI of patients with PAN have been recently describedObjectives:to describe MRI of legs findings in patients with PAN in a tertiary center from Medellin-Colombia.Methods:it was performed a retrospective cross-sectional descriptive study of 15 adult patients who were clinically assessed as having PAN and who had undergone MRI of legs between January 2011 and December 2019. Characteristics already informed in previous studies, affected structures (muscle, subcutaneous tissue, and bone) and pattern of hyperintensities were described as diffuse pattern (signal alterations affecting the entire area of the involved muscle), patched pattern (areas of hyperintensities alternating areas of normal muscle signal intensity), and fluffy nodular pattern or cotton-wool appearance (round hyperintense lesions with fluffy margins centered on blood vessels).Results:clinical characteristics:myalgia, especially calf pain, was the most frequent muscular complaint; other clinical manifestations were: constitutional symptoms (80%), arthralgias or arthritis (50%), mono/polyneuropathy (33%), subcutaneous nodules (33%), livedo reticularis (20%), lower limbs ulcers (13%), abdominal symptoms (13%), and purpura (7%).MRI findings:bilateral muscular edema was found in all patients (100%), fatty infiltration (20%), edema of the subcutaneous cellular tissue (20%), and muscular atrophy (13%) were also described. A diffuse pattern occurred in 46% (n=7) of patients (figure panel A), a patched pattern (figure panel B) in 46% (n=7), and a fluffy nodular pattern or cotton-wool appearance (figure panel C) in 6% (n=1). The most frequently affected muscular group was gastrocnemius and soleus (67%), followed by anterior tibialis (27%), plantar, long peroneus, first finger flexors, and long flexors only affected in 7%. Bone involvement was found in 53%, being the tibia the most affected, followed by the fibula and the calcaneus. MRI led to guide the site of muscle biopsy to prove histological medium-size vasculitis in half of the patients.Conclusion:in patients with PAN suspicion who have muscular complaints, especially calf pain, MRI arises as an important diagnostic tool, and also as a guide to muscular biopsy to prove vasculitis. The patterns associated with PAN are diffuse, patched or fluffy nodular hyperintensities in gastrocnemius and soleus with or without bone compromise.References:[1]Kang, Y. et al. Muscle involvement in polyarteritis nodosa: Report of eight cases with characteristic contrast enhancement pattern on MRI. Am. J. Roentgenol. 206, 378–384 (2016).[2]Hofman DM, Lems WF, Witkamp TD, Putte VD, Bijlsma JW. Demonstration of calf abnormalities by magnetic resonance imaging in polyarteritis nodosa. Clin Rheumatol 1992; 11:402–404.FigureDisclosure of Interests:None declared
Collapse
|
23
|
Torres F, Jaramillo Arroyave D, Muñoz C, Hernandez L, Vásquez G, Restrepo Escobar M, González LA, Vanegas A. AB0487 TAKAYASU’S ARTERITIS: RECOGNIZING AN OLD ENEMY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.6605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Takayasu’s arteritis (AT) is a systemic vasculitis that affects large vessels, mainly the aorta, its branches and the pulmonary arteries. There are few data on their behavior in our region.Objectives:to describe the clinical and angiographic characteristics and outcomes of a group of patients with AT.Methods:a cross-sectional, retrospective study based on a secondary source taken from two high complexity hospitals in Medellin - Colombia between August 2011 and December 2018.Results:medical records of 41 patients were evaluated, 87.5% met the 1990 ACR criteria of AT. The majority were women (95.1%), with a median age at the time of diagnosis of 22 years (IR 52), 11 patients (26.8%) were over 40 years old at debut. The median delay in diagnosis was 12 months (IR: 167). Systemic symptoms included general malaise (29.3%), weight loss (29.3%) and fever (19.5%); the main vascular manifestations were hypertension and blood pressure difference (61%), headache (39%), upper limb claudication (31.7%), dyspnea (29.3%), angina (26.8%) and carotidinia (22%). Most frequent findings on physical examination were pulse absence or decrease (78%) and subclavian murmur (53.7%). ESR and CRP were found high in 85.3% and 22%, respectively. Angiographic studies revealed stenosis or occlusion in multiple arterial territories, being the stenosis of the left subclavian artery the most frequent lesion (68.3%), followed by the involvement of the abdominal aorta (58.5%) and thoracic (51%). The distribution according to Hata-Numano classification was: type V (58.5%), type I (17.1%) and type IIa (7.3%), indicating complex vascular lesions and associated serious complications. Abnormalities of the renal arteries, pulmonary arteries involvement, and aortic insufficiency were present in 39%, 14.6%, and 7.3% respectively. Seventy-five percent of patients had active disease, glucocorticoids were the main treatment in 90.2% of the cases, used isolated (2.4%) or in combination with other immunosuppressants (87.8%), including methotrexate (75.6%), azathioprine (26.8%) and cyclophosphamide (14.6%); vascular interventions were performed in 11 patients (26.8%). Most relevant vascular complications were renovascular hypertension (26.8%), stroke (19.5%), chronic kidney disease (19.5%) and chronic heart failure (17.1%). From the clinical point of view, our findings were similar to those shown in series from Brazil, Japan, and Turkey. Contrary to what was reported in other series, carotidinia was a finding that occurred in almost a quarter of our patients (23%) and maybe one of the initial symptoms of the disease. The findings of the vascular physical examination are similar to those reported by the IRAVAS group, where the asymmetry of the pulses was most frequent, followed by the presence of murmurs and the difference in blood pressure, claudication being less frequent in the upper and lower limbs.Conclusion:patients in this series are characterized by having an extensive disease partly due to a late diagnosis, with a high percentage of complications associated with vascular stenotic compromise, which generates morbidity and impact on the quality of life.References:[1]Sato EI, et al. Takayasu arteritis. Treatment and prognosis in a university center in Brazil, Int J Cardiol. 2000; 75 Suppl 1: S163-6.[2]Arnaud L, et al. Takayasu arteritis in France: a single-center retrospective study of 82 cases comparing white, North African, and black patients. Medicine (Baltimore). 2010; 89(1): 1-17.Disclosure of Interests: :None declared
Collapse
|
24
|
Torres F, Leon L, Vanegas A, Muñoz C, González LA, Jaramillo D. AB0535 ARE THE NEUTROPHIL/LYMPHOCYTE RATIO (NLR) AND PLATELET/LYMPHOCYTE RATIO (PLR) USEFUL TO COMPARED WITH ACUTE PHASE REACTANTS (ESR/CRP) FOR DIAGNOSIS AND PROGNOSIS OF PATIENTS WITH ACTIVE TAKAYASU’S ARTERITIS (TAK)?: AN ANALYSIS BASED ON ROC AND KAPLAN-MEIER CURVES IN A LATIN AMERICAN POPULATION. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:The NIH criteria are the main measure to determine activity in TAK. NLR and PLR appear promising to predict disease activity(1). TAK is one of the most frequent vasculitis in Colombia with a prevalence of 13.3%; however, in more recent years the information is sparse about TAK clinical behavior in our region, which leads to a late diagnosis. Although survival has improved with immunosuppressive treatment, relapses remain high especially in the first year of diagnosisObjectives:Compare NLR and PLR with ESR/CRP to predict TAK activityShow survival and relapse in patients with TAK followed to 7 yMethods:Retrospective cohort of 43 patients with TAK between 2011-2018 with prospective follow-up of relapses and mortality. 88% fulfilled the ACR 1990 criteria. The disease activity was determined according to NIH criteria: active disease (n=34) and inactive disease (n=9). Through bivariate analysis, we compared the clinical and radiologic characteristics between age groups (table 1) using the Pearson test and Wilcoxon range test. Value of p <0.05 was statistically significant. Survival and relapse analysis were performed using Kaplan-Meier plots. Sensitivity (Sn), specificity (Sp) and area under the curve (AUC) were determined for NLR, PLR, ESR and CRP by receiver-operating curves (ROC) compared to NIH criteria.Table 1.Comparison of Clinical Features in Patients with TAKNo (%) of PatientsAge at diagnosis≤40 y (n=32)Age at diagnosis≥40 y(n=11)P valueFemale30 (94)11 (100)0.39Age at symptom onset (years), median: (Interquartile range –IQR-)20 (17-25)52 (47-57)0.110Time from symptom onset to diagnosis (months) median (IQR)9.5 (2-15)36 (1.5-24)0.774Smoking2 (6)6 (54)0.002Dyslipidemia7 (22)6 (54)0.042ACR Criteria 1990Claudication of extremities14 (43)5 (45)0.922Upper extremities blood pressure discrepancy > 10 mmHg19 (59)6 (54)0.779Decreased brachial artery pulse24 (75)9 (82)0.644Subclavian artery or aorta bruit19 (59)6 (54)0.774Arteriographic abnormality27/27 (100)11/11 (100)1.0ESR (mm/h), median (IQR)56 (23-115)38 (33-76)0.011CRP (mg/dL), median (IQR)1.35 (0.4-3.4)3 (1.49-18.5)0.020Creatinine (mg/dL), median (IQR)0.72 (0.6-0.83)0.84 (0.75-1)0.007Hata-Numano classification I15%18% IIa6%9% IIb6% III6% IV3%9% V59%64%Results:41 patients were women (96%) with a median age at diagnosis of 22 y and an interval from the onset of disease to diagnosis of 12 months (IR:1-168 m). The population over 40 years had a greater comorbidities burden (54% had history of smoking and dyslipidemia) and a major interval between the onset of disease and the diagnosis (36 months vs 9.5 months). Most frequent vascular phenotypes were types V (62%) and I (16%). NLR and PLR showed poor performance to predict activity compared with CRP; NLR level of 1.74 showed to be the predictive cut-off value for active TAK (Sn: 85.3%, Sp: 37.5%, AUC = 0.563). PLR level of 112.5 was found to be the predictive cut-off value for active TAK (Sn: 76.5%, Sp: 50%, AUC = 0.517). The CRP was the most accurate biomarker (Sn: 79.4%, Sp: 75%, AUC = 0.761) while the ESR was lower to predict activity (Sn: 63.6%, Sp: 75%, AUC = 0.598) (figure 1). At 5 years, survival was 83% and 50% of patients had presented at least one relapse (figure 2)Conclusion:Our data does not support the use of NLR or PLR to differentiate relapse and remission in TAK. CRP had better diagnostic performance than ESR in the prediction of activity compared to NIH criteria. The 5-year survival in this cohort is below that reported after 1985 (reported survival: 90-96%)(2)References :[1]Pan L, et al. Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio associated with disease activity in patients with Takayasu’s arteritis: a case-control study. BMJ Open 2017; 7: e014451[2]Schmidt J, et al. Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients, Mayo Clin Proc. 2013; 88(8): 822-30Disclosure of Interests:None declared
Collapse
|
25
|
Peinado Acevedo JS, Calle M, Medina A, Jaramillo Arroyave D, Vanegas A, González LA, Vásquez G, Restrepo Escobar M, Muñoz C. AB0514 CALF PAIN, KEY POINT IN THE DIAGNOSIS OF POLYARTERITIS NODOSA. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.6578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:polyarteritis nodosa (PAN) is a primary systemic vasculitis that is becoming a rare disease in part by the decrease in hepatitis B virus (HBV) infection due to widespread vaccination. It is characterized by a full vast constellation of nonspecific clinical manifestations, which sometimes delays and makes it difficult to diagnose. Still, muscle involvement is a feature that could guide the clinician.Objectives:to describe the main clinical and laboratory characteristics of patients with PAN and to confirm the frequency of muscle involvement.Methods:retrospective cross-sectional descriptive study of 23 adult patients diagnosed with PAN between January 2011 and December 2018 in two high complexity hospitals in Medellin-Colombia.Results:twenty-three patients met ACR 1990 classification criteria for PAN, 52% were men with a median age of 51 (IR 36-60), 78.3% were newly diagnosed, and only two patients (8.7%) had HBV infection. General symptoms (found in 95% of the patients), cutaneous (82%), and articular (56%) were the most frequent manifestations. Among systemic symptoms, myalgia, especially calf pain, was the most common characteristic (78.3%), followed by weight loss (73.9%), fatigue (69.3%), and fever (59.3%). Laboratory findings and severity scores are shown in the table. Angiography was performed in 27.3% of patients, finding splanchnic (renal, hepatic and splenic) microaneurysms (17.4%), stenosis (13%), and renal infarction (4.3%). Fourteen patients (61%) had at least one positive biopsy documenting medium-sized artery vasculitis, mainly skin, muscle, nerve, or both; 9 (39%) had normal or inconclusive biopsy findings. All patients received high daily doses of prednisolone (50 ± 16 mg); 52.2% required cyclophosphamide, 30.4% azathioprine, 17.4% methotrexate, 8.7% rituximab, 4.3% dapsone and 4.3% plasmapheresis; acetylsalicylic acid was given to half of the patients and only one required antiviral therapy for HBV. With treatment, 87% improved; 22.7% had an infection, and 8.7% of patients died.Conclusion:myalgia was the main characteristics of our PAN patients, especially in calves, and its presence in patients with other general, skin or articular symptoms should raise the suspect of this vasculitis.References:[1]Karadag O, Jayne DJ. Polyarteritis nodosa revisited: a review of historical approaches, subphenotypes and a research agenda. Clin Exp Rheumatol. 2018;36 Suppl 111(2):135–142.[2]Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62(2):616–626.TableCharacteristicPAN patients (n=23)CRP (mean and SD in mg/dl)6.3 ± 8.51ESR (mean and SD in mm/h)84 ± 38CPK (median and IR in U/L) normal value < 18076 (66)FFS (mean)1BVAS (median and IR)17 (7)PAN: polyarteritis nodosa; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; CPK: creatine phosphokinase; FFS: five factor score; BVAS: Birmingham Vasculitis Activity Score; SD: standard desviation; IR (interquartile range)Disclosure of Interests:None declared
Collapse
|
26
|
Medina A, Calle M, Eraso R, Hernandez L, Peinado Acevedo JS, Velasquez M, Vanegas A, Jaramillo Arroyave D, Muñoz C. FRI0468 SYSTEMIC AND CUTANEOUS POLYARTERITIS NODOSA IN COLOMBIAN PEDIATRIC PATIENTS: CUTANEOUS POLYARTERITIS IS NOT SO BENIGN. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.6512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Polyarteritis nodosa (PAN) is the third most frequent vasculitis in pediatrics, Cutaneous PAN (CPAN) being more common that Systemic PAN (SPAN). CPAN is frequently described as a benign disease. In children, PAN onset is frequent between 9 and 11 years of age, with no sex differences, and its clinical features may be nonspecific.Objectives:To characterize pediatric patients who were diagnosed with CPAN and SPAN and to compare their clinical features, treatments, and outcome.Methods:A descriptive study was conducted in two centers from Medellin- Colombia, using retrospective data from January 2010 to December 2019. Patients under 18 years of age classified as PAN according to EULAR/PRINTO/PRES(1) criteria were included. CPAN patients were defined according to EULAR/PRES definition (2). Data from medical records were registered, and were expressed in median and ranges and mean and standard deviation (SD) according to their distribution. A univariate analysis was carried out by comparing signs, symptoms, and treatment between CPAN and SPAN, and ap-value < 0,05was considered as significant.Results:Twenty patients were included. The median age at diagnosis was ten years. 60% were boys. The median follow-up period was 27 months. CPAN was diagnosed in 11 (55%) and SPAN in 9 patients (45%). The most frequent symptoms were cutaneous manifestations (95%), fever (60%) and Calf Pain (55%). Mucosal ulcers were described in four patients; 3 of them were defined as CPAN. Lingual necrosis was present in two CPAN, and peripheral nervous system involvement was found in one SPAN and two CPAN patients in skin affected with lesions; even though, no significant statistical differences between CPAN and SPAN were found in constitutional, cutaneous, muscle-skeletal symptoms, and acute phase reactants. Arteriographic anomalies as hepatic and renal microaneurysms, carotidal aneurysms without aortic involvement, and renal infarction were found in one patient each. Skin Biopsy was performed in 18 patients, being compatible with PAN in 16. All PAN patients (CPAN and SPAN) required treatment with glucocorticoids. None of the patients died during the follow-up period.Conclusion:In this Colombian pediatric cohort of PAN patients, the disease was more common in boys than girls, and CPAN was more frequent than SPAN, as already been described. As is evident in this cohort, although CPAN has been considered a benign disease, these patients may be severely ill, requiring glucocorticoid treatment. Pediatric CPAN patients should be strictly followed with particular attention to identify systemic involvement, considering that constitutional, cutaneous, and muscle-skeletal features may be very similar between CPAN and SPAN.References:[1]Ozen S, Pistorio A, Iusan S, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010 May;69(5):798–806.[2]Ozen S, Ruperto N, Dillon M, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65(7):936–41.Disclosure of Interests:None declared
Collapse
|
27
|
Laporte-Amargos J, Gudiol C, Arnan M, Puerta-Alcalde P, Carmona-Torre F, Huguet M, Albasanz-Puig A, Parody R, Garcia-Vidal C, Del Pozo JL, Batlle M, Tebé C, Rigo-Bonnin R, Muñoz C, Padullés A, Tubau F, Videla S, Sureda A, Carratalà J. Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE). Trials 2020; 21:412. [PMID: 32423462 PMCID: PMC7236103 DOI: 10.1186/s13063-020-04323-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Accepted: 04/10/2020] [Indexed: 12/26/2022] Open
Abstract
Background Febrile neutropaenia (FN) is a very common complication in patients with haematological malignancies and is associated with considerable morbidity and mortality. Broad-spectrum antipseudomonal β-lactam antibiotics (BLA) are routinely used for the treatment of cancer patients with FN. However, the clinical efficacy of BLA may be diminished in these patients because they present with pathophysiological variations that compromise the pharmacokinetic (PK) parameters of these antibiotics. Optimised administration of BLA in prolonged infusions has demonstrated better clinical outcomes in critically ill patients. However, there is a paucity of data on the usefulness of this strategy in patients with FN. The aim of this study is to test the hypothesis that the administration of BLA would be clinically more effective by extended infusion (EI) than by intermittent infusion (II) in haematological patients with FN. Methods A randomised, multicentre, open-label, superiority clinical trial will be performed. Patients with haematological malignancies undergoing chemotherapy or haematopoietic stem-cell transplant and who have FN and receive empirical antibiotic therapy with cefepime, piperacillin-tazobactam or meropenem will be randomised (1:1) to receive the antibiotic by EI (during half the time of the dosing interval) in the study group, or by II (30 min) in the control group. The primary endpoint will be clinical efficacy, defined as defervescence without modifying the antibiotic treatment administered within the first 5 days of therapy. The primary endpoint will be analysed in the intention-to-treat population. The secondary endpoints will be pharmacokinetic/pharmacodynamic (PK/PD) target achievement, bacteraemia clearance, decrease in C-reactive protein, overall (30-day) case-fatality rate, adverse events and development of a population PK model of the BLA studied. Discussion Data on the usefulness of BLA administration in patients with FN are scant. Only three clinical studies addressing this issue have been published thus far, with contradictory results. Moreover, these studies had some methodological flaws that limit the interpretation of their findings. If this randomised, multicentre, phase IV, open-label, superiority clinical trial validates the hypothesis that the administration of BLA is clinically more effective by EI than by II in haematological patients with FN, then the daily routine management of these high-risk patients could be changed to improve their outcomes. Trial registration European Clinical Trials Database: EudraCT 2018–001476-37. ClinicalTrials.gov, ID: NCT04233996.
Collapse
Affiliation(s)
- J Laporte-Amargos
- Infectious Diseases Department Hospital Universitari Bellvitge, Institut d'Investigació Biomedica de Bellvitge (IDIBELL), Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain
| | - C Gudiol
- Infectious Diseases Department Hospital Universitari Bellvitge, Institut d'Investigació Biomedica de Bellvitge (IDIBELL), Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain. .,University of Barcelona, Barcelona, Spain. .,Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Sevilla, Spain. .,Institut Català d'Oncologia, IDIBELL, Barcelona, Spain.
| | - M Arnan
- Clinical Haematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Barcelona, Spain
| | - P Puerta-Alcalde
- Infectious Diseases Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
| | - F Carmona-Torre
- Infectious Diseases Department, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain
| | - M Huguet
- Clinical Haematology Department, Institut Català d'Oncologia-Badalona, Institut Josep Carreras (IJC), Hospital Germans Trias i Pujol, Barcelona, Spain
| | - A Albasanz-Puig
- Infectious Diseases Department Hospital Universitari Bellvitge, Institut d'Investigació Biomedica de Bellvitge (IDIBELL), Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain.,Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Sevilla, Spain
| | - R Parody
- Clinical Haematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Barcelona, Spain
| | - C Garcia-Vidal
- Infectious Diseases Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
| | - J L Del Pozo
- Infectious Diseases Department, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain
| | - M Batlle
- Clinical Haematology Department, Institut Català d'Oncologia-Badalona, Institut Josep Carreras (IJC), Hospital Germans Trias i Pujol, Barcelona, Spain
| | - C Tebé
- Biostatistics Unit, IDIBELL, Barcelona, Spain
| | - R Rigo-Bonnin
- Clinical Laboratory Department, Hospital Universitari Bellvitge, IDIBELL, Barcelona, Spain
| | - C Muñoz
- Pharmacy Department, Clinical Trial Unit, Institut Català d'Oncologia, IDIBELL, Barcelona, Spain
| | - A Padullés
- Pharmacy Department, Hospital Universitari Bellvitge, IDIBELL, Barcelona, Spain
| | - F Tubau
- Microbiology Department, Hospital Universitari Bellvitge, IDIBELL, Barcelona, Spain
| | - S Videla
- Clinical Pharmacology Department, Hospital Universitari Bellvitge, IDIBELL, Barcelona, Spain
| | - A Sureda
- Clinical Haematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, Barcelona, Spain
| | - J Carratalà
- Infectious Diseases Department Hospital Universitari Bellvitge, Institut d'Investigació Biomedica de Bellvitge (IDIBELL), Feixa Llarga SN, 08907, L'Hospitalet de Llobregat, Barcelona, Spain.,University of Barcelona, Barcelona, Spain.,Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Sevilla, Spain
| |
Collapse
|
28
|
Reventun P, Sanchez-Esteban S, Cook A, Cuadrado I, Roza C, Moreno-Gomez-Toledano R, Muñoz C, Zaragoza C, Bosch RJ, Saura M. Bisphenol A induces coronary endothelial cell necroptosis by activating RIP3/CamKII dependent pathway. Sci Rep 2020; 10:4190. [PMID: 32144343 PMCID: PMC7060177 DOI: 10.1038/s41598-020-61014-1] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2019] [Accepted: 02/20/2020] [Indexed: 02/07/2023] Open
Abstract
Epidemiological studies link long term exposure to xenoestrogen Bisphenol-A to adverse cardiovascular effects. Our previous results show that BPA induces hypertension by a mechanism involving CamKII activation and increased redox stress caused by eNOS uncoupling. Recently, CamKII sustained activation has been recognized as a central mediator of programmed cell death in cardiovascular diseases, including necroptosis. However, the role of necroptosis in cardiac response to BPA had not yet been explored. Mice exposed to BPA for 16 weeks showed altered heart function, electrical conduction, and increased blood pressure. Besides, a stress test showed ST-segment depression, indicative of cardiac ischemia. The hearts exhibited cardiac hypertrophy and reduced vascularization, interstitial edema, and large hemorrhagic foci accompanied by fibrinogen deposits. BPA initiated a cardiac inflammatory response, up-regulation of M1 macrophage polarization, and increased oxidative stress, coinciding with the increased expression of CamKII and the necroptotic effector RIP3. In addition, cell death was especially evident in coronary endothelial cells within hemorrhagic areas, and Evans blue extravasation indicated a vascular leak in response to Bisphenol-A. Consistent with the in vivo findings, BPA increased the necroptosis/apoptosis ratio, the expression of RIP3, and CamKII activation in endothelial cells. Necrostatin-1, an inhibitor of necroptosis, alleviated BPA induced cardiac dysfunction and prevented the inflammatory and hemorrhagic response in mice. Mechanistically, silencing of RIP3 reversed BPA-induced necroptosis and CamKII activation in endothelial cells, while inhibition of CamKII activation by KN-93 had no effect on RIP3 expression but decreased necroptotic cell death suggesting that BPA induced necroptosis is mediated by a RIP 3/CamKII dependent pathway. Our results reveal a novel pathogenic role of BPA on the coronary circulation. BPA induces endothelial cell necroptosis, promotes the weakening of coronary vascular wall, which caused internal ventricular hemorrhages, delaying the reparative process and ultimately leading to cardiac dysfunction.
Collapse
Affiliation(s)
- P Reventun
- Biology systems Dpt, University Alcalá (UAH), Madrid, Spain
| | | | - A Cook
- Biology systems Dpt, University Alcalá (UAH), Madrid, Spain
| | - I Cuadrado
- Pharmacology, Pharmacognosy and Botanics Dpt, Complutense University (UCM), Madrid, Spain
| | - C Roza
- Biology systems Dpt, University Alcalá (UAH), Madrid, Spain
| | | | - C Muñoz
- Biology systems Dpt, University Alcalá (UAH), Madrid, Spain
| | - C Zaragoza
- Joint Unit of Cardiovascular Research University Francisco de Vitoria and Hospital Ramon y Cajal, Madrid, Spain
| | - R J Bosch
- Biology systems Dpt, University Alcalá (UAH), Madrid, Spain
| | - M Saura
- Biology systems Dpt, University Alcalá (UAH), Madrid, Spain.
| |
Collapse
|
29
|
Rios-Romenets S, Giraldo-Chica M, López H, Piedrahita F, Ramos C, Acosta-Baena N, Muñoz C, Ospina P, Tobón C, Cho W, Ward M, Langbaum JB, Tariot PN, Reiman EM, Lopera F. The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial. J Prev Alzheimers Dis 2019; 5:49-54. [PMID: 29405233 DOI: 10.14283/jpad.2017.44] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) trial evaluates the anti-amyloid-β antibody crenezumab in cognitively unimpaired persons who, based on genetic background and age, are at high imminent risk of clinical progression, and provides a powerful test of the amyloid hypothesis. The Neurosciences Group of Antioquia implemented a pre-screening process with the goals of decreasing screen failures and identifying participants most likely to adhere to trial requirements of the API ADAD trial in cognitively unimpaired members of Presenilin1 E280A mutation kindreds. The pre-screening failure rate was 48.2%: the primary reason was expected inability to comply with the protocol, chiefly due to work requirements. More carriers compared to non-carriers, and more males compared to females, failed pre-screening. Carriers with illiteracy or learning/comprehension difficulties failed pre-screening more than non-carriers. With the Colombian API Registry and our prescreening efforts, we randomized 169 30-60 year-old cognitively unimpaired carriers and 83 non-carriers who agreed to participate in the trial for at least 60 months. Our findings suggest multiple benefits of implementing a pre-screening process for enrolling prevention trials in ADAD.
Collapse
Affiliation(s)
- S Rios-Romenets
- Silvia Rios-Romenets, MD, Medical Director and Deputy API Colombia, Neuroscience Group of Antioquia, Calle 62 No. 52 - 59, Medellín, Antioquia, Colombia, Phone: 57-4-2196424, 2196425, Fax: 57-4-2196444,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Castellano J, Navarro A, Molins L, Canals J, Marrades R, Viñolas N, Moises J, Casadevall M, Li Y, Han B, Martinez D, Martin J, Garisoain A, Muñoz C, Ramirez J, Monzo M. Pulmonary tumour-draining vein exosomal lincRNA-p21 levels impacts non-small cell lung cancer prognosis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz258.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Barrera A, Alhambra M, Molina M, Rebollo Á, Alcántara M, León S, Moreno P, Muñoz C, Manzano G, Padillo J, Calañas A, Gutiérrez J, Gálvez M. MON-PO368: Nutritional Status and Immunonutrition in Patients Intervened for Total Laringectomy for Cancer. Clin Nutr 2019. [DOI: 10.1016/s0261-5614(19)32202-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
32
|
Ceniceros L, Álvarez R, Muñoz C, Sanz-García E, Ugidos L, Rodriguez-Pascual J, Hernandez S, Gomez P, Garcia-Rico E, Cubillo A. Clinical and molecular characteristics of biliary tract carcinoma using next-generation sequencing. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Risueño J, Spitzová T, Bernal LJ, Muñoz C, López MC, Thomas MC, Infante JJ, Volf P, Berriatua E. Longitudinal monitoring of anti-saliva antibodies as markers of repellent efficacy against Phlebotomus perniciosus and Phlebotomus papatasi in dogs. Med Vet Entomol 2019; 33:99-109. [PMID: 30450832 DOI: 10.1111/mve.12343] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/25/2018] [Revised: 08/25/2018] [Accepted: 09/01/2018] [Indexed: 06/09/2023]
Abstract
A 2-year longitudinal study of enzyme-linked immunosorbent assay (ELISA) antibodies against Phlebotomus perniciosus and Phlebotomus papatasi (Diptera: Psychodidae) sandfly saliva was performed in 32 Beagle dogs treated preventively with an imidacloprid-permethrin topical insecticide in an endemic area in Spain. Dogs were grouped into three sandfly exposure groups according to the time of inclusion in the study. Assays analysed immunoglobulin G (IgG) against salivary gland homogenates (SGH) of both species and recombinant P. papatasi rSP32 and P. perniciosus rSP03B proteins in serum. The dogs were participating in a Leishmania infantum (Kinetoplastida: Trypanosomatidae) vaccine trial and were experimentally infected with the parasite in the second year. No dog acquired natural L. infantum infections during the first year, but most developed anti-saliva antibodies, and median log-transformed optical densities (LODs) were seasonal, mimicking those of local sandflies. This indicates that the repellent efficacy of the insecticide used is below 100%. Multi-level modelling of LODs revealed variability among dogs, autocorrelation and differences according to the salivary antigen and the dog's age. However, dog seroprevalence, estimated using pre-exposure LODs as cut-offs, was relatively low. This, and the fact that dogs did not become naturally infected with L. infantum, would support the efficacy and usefulness of this imidacloprid-permethrin topical insecticide in canine leishmaniasis control.
Collapse
Affiliation(s)
- J Risueño
- Department of Animal Health, Faculty of Veterinary Science, Regional Campus of International Excellence 'Campus Mare Nostrum', University of Murcia, Murcia, Spain
| | - T Spitzová
- Department of Parasitology, Faculty of Science, Charles University in Prague, Prague, Czech Republic
| | - L J Bernal
- Department of Medicine and Surgery, Faculty of Veterinary Science, Regional Campus of International Excellence 'Campus Mare Nostrum', University of Murcia, Murcia, Spain
| | - C Muñoz
- Department of Animal Health, Faculty of Veterinary Science, Regional Campus of International Excellence 'Campus Mare Nostrum', University of Murcia, Murcia, Spain
| | - M C López
- Molecular Biology Department, Institute of Parasitology and Biomedicine 'López Neyra', Consejo Superior de Investigaciones Científicas, Granada, Spain
| | - M C Thomas
- Molecular Biology Department, Institute of Parasitology and Biomedicine 'López Neyra', Consejo Superior de Investigaciones Científicas, Granada, Spain
| | - J J Infante
- Bioorganic Research and Services, SA, Jerez de la Frontera, Spain
| | - P Volf
- Department of Parasitology, Faculty of Science, Charles University in Prague, Prague, Czech Republic
| | - E Berriatua
- Department of Animal Health, Faculty of Veterinary Science, Regional Campus of International Excellence 'Campus Mare Nostrum', University of Murcia, Murcia, Spain
| |
Collapse
|
34
|
Velez R, Ballart C, Domenech E, Abras A, Fernández-Arévalo A, Gómez SA, Tebar S, Muñoz C, Cairó J, Gállego M. Seroprevalence of canine Leishmania infantum infection in the Mediterranean region and identification of risk factors: The example of North-Eastern and Pyrenean areas of Spain. Prev Vet Med 2018; 162:67-75. [PMID: 30621900 DOI: 10.1016/j.prevetmed.2018.10.015] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2018] [Revised: 10/20/2018] [Accepted: 10/22/2018] [Indexed: 11/26/2022]
Abstract
The Mediterranean basin is an endemic region for canine leishmaniosis (CanL), where it represents a major veterinary problem and raises human health concerns. However, the distribution of the disease is heterogeneous and not all countries and locations have been equally studied and characterized. This work describes the situation of CanL in Girona province (Catalonia, Spain), for which no data has been previously reported, and presents a relevant study to exemplify other areas with similar characteristics across the region. Four cross-sectional seroprevalence surveys were performed from 2012 to 2016 throughout the province, including 36 sampling stations in 26 localities and a total of 593 dogs. For each animal, individual and location variables were also collected. Additionally, each dog owner answered a questionnaire about their knowledge of CanL and preventive methods used. Blood samples were analysed by an in-house ELISA and a mixed logistic regression model was used to assess the relationship between pre-determined variables and dog seropositivity. A Spearman's correlation was used to assess the association between dog owners' perceived risk of CanL and Leishmania infantum seropositivity in dogs at a given location. The overall true seroprevalence estimated for Girona province was 19.5% (95%CI: 15.5-23.5), of which only 6.8% (10/146) were considered symptomatic. Age of the dog [OR = 1.21 (95%CI: 1.11-1.31); p < 0.001] and altitude [OR = 0.02 (95%CI: 0.001-0.19); p = 0.001] were identified as risk factors for the infection. The results obtained in this study are expected to aid in the implementation of directed control programmes in CanL endemic areas throughout Europe, as well as to provide suitable data for the design of better risk assessment maps of the disease.
Collapse
Affiliation(s)
- R Velez
- ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.
| | - C Ballart
- ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.
| | - E Domenech
- Hospital Veterinari Canis, Girona, Spain.
| | - A Abras
- ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain; Laboratori d'Ictiologia Genètica, Departament de Biologia, Universitat de Girona, Girona, Spain.
| | - A Fernández-Arévalo
- ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain; Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
| | - S A Gómez
- ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
| | - S Tebar
- Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.
| | - C Muñoz
- Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.
| | - J Cairó
- Hospital Veterinari Canis, Girona, Spain.
| | - M Gállego
- ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.
| |
Collapse
|
35
|
Muñoz C, Gonzalez F. Laparoscopic treatment of type II Mirizzi Syndrome with common bile duct plasty. J Visc Surg 2018; 155:507-508. [PMID: 30220477 DOI: 10.1016/j.jviscsurg.2018.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- C Muñoz
- Upper GI & HPB Unit, Hospital Regional de Talca, 1, Norte #19990, Talca, Chile; Surgery Departament, Universidad Católica del Maule, Talca, Chile.
| | - F Gonzalez
- Upper GI & HPB Unit, Hospital Regional de Talca, 1, Norte #19990, Talca, Chile; Surgery Departament, Universidad Católica del Maule, Talca, Chile
| |
Collapse
|
36
|
Julià M, Consuegra-Fernández M, Guilabert A, Muñoz C, Esteve A, Armiger-Borràs N, Santiago F, Arias M, Romaní J, Ferrándiz C, Carrascosa J, Pedrosa E, Alsina-Gibert M, Lozano F, Mascaró-Galy J. Corrigendum to “Genetically defined variants of toll-like receptors 3, 7 and 9 as phenotype and risk modifier factors for psoriasis” [89 (March (3)) (2018) 301–304]. J Dermatol Sci 2018; 91:342. [DOI: 10.1016/j.jdermsci.2018.03.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
37
|
Echeverria L, Martin-Muñoz MF, Martorell C, Belver MT, Alonso Lebrero E, Zapatero L, Fuentes V, Piqué M, Plaza A, Muñoz C, Martorell A, Blasco C, Villa B, Gómez C, Nevot S, García JM, Madero R. Clinical and immunological profile of children aged 5-9 years with persistent egg allergy before oral immunotherapy with egg. A multicenter, randomized controlled trial of the Spanish Society of Pediatric Allergy, Asthma and Clinical Immunology (SEICAP). Allergol Immunopathol (Madr) 2018; 46:415-420. [PMID: 29804794 DOI: 10.1016/j.aller.2018.01.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2017] [Revised: 01/18/2018] [Accepted: 01/25/2018] [Indexed: 11/15/2022]
Abstract
BACKGROUND In children with egg protein allergy (EA), the probability of overcoming the allergy decreases with age, and the possibility of suffering severe adverse reactions as a consequence of dietetic transgressions results in worsened quality of life. One treatment option in such cases is oral immunotherapy (OIT) with foods. METHODS We present a cohort of children with EA scheduled for OIT with pasteurized raw egg white, describing their clinical and allergic characteristics before the start of OIT. RESULTS The median age was six years, and 93% of the patients also suffered other allergies (58% asthma and 38.6% allergy to more than two food groups). In the last year, 14.8% had suffered a severe reaction due to dietetic transgression with egg. The median IgE specific of egg white titer was 38.5kU/l. A double-blind placebo-controlled food challenge with cooked egg white was performed, and if the test proved positive, it was repeated with pasteurized raw egg white. The mean symptoms-provoking dose was 1.26g and 0.55g for cooked egg white and raw egg white, respectively. An IgE specific of ovomucoid titer of <2.045kU/l differentiated those patients that tolerated cooked egg white. CONCLUSIONS OIT with egg is regarded as an option in patients with persistent egg allergy. In the previous challenge test, an IgE specific of ovomucoid titer of <2.045kU/l differentiates those patients that tolerate cooked egg white.
Collapse
Affiliation(s)
- L Echeverria
- Severo Ochoa University Hospital, Leganés, Madrid, Spain.
| | - M F Martin-Muñoz
- Idipaz, Institute for Health Research, La Paz University Hospital, Madrid, Spain
| | - C Martorell
- Valencia University General Hospital, Valencia, Spain
| | - M T Belver
- Idipaz, Institute for Health Research, La Paz University Hospital, Madrid, Spain
| | | | - L Zapatero
- Gregorio Marañón Hospital, Madrid, Spain
| | - V Fuentes
- Gregorio Marañón Hospital, Madrid, Spain
| | - M Piqué
- San Juan de Dios Hospital, Barcelona, Spain
| | - A Plaza
- San Juan de Dios Hospital, Barcelona, Spain
| | - C Muñoz
- Carlos Haya Hospital, Málaga, Spain
| | - A Martorell
- Valencia University General Hospital, Valencia, Spain
| | - C Blasco
- Vall Hebrón Hospital, Barcelona, Spain
| | - B Villa
- Vall Hebrón Hospital, Barcelona, Spain
| | - C Gómez
- Fundación Althaia San Juan de Dios Hospital, Sabadell, Barcelona, Spain
| | - S Nevot
- Fundación Althaia San Juan de Dios Hospital, Sabadell, Barcelona, Spain
| | | | - R Madero
- Idipaz, Institute for Health Research, La Paz University Hospital, Madrid, Spain
| |
Collapse
|
38
|
Pérez-Prieto L, González-Verdugo H, Muñoz C. Effect of grazing rotation length on milk production and composition of dairy cows strip-grazing at the same herbage allowance during a dry summer. Livest Sci 2018. [DOI: 10.1016/j.livsci.2018.06.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
39
|
Hristov A, Kebreab E, Niu M, Oh J, Bannink A, Bayat A, Boland T, Brito A, Casper D, Crompton L, Dijkstra J, Eugène M, Garnsworthy P, Haque N, Hellwing A, Huhtanen P, Kreuzer M, Kuhla B, Lund P, Madsen J, Martin C, Moate P, Muetzel S, Muñoz C, Peiren N, Powell J, Reynolds C, Schwarm A, Shingfield K, Storlien T, Weisbjerg M, Yáñez-Ruiz D, Yu Z. Symposium review: Uncertainties in enteric methane inventories, measurement techniques, and prediction models. J Dairy Sci 2018; 101:6655-6674. [DOI: 10.3168/jds.2017-13536] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Accepted: 03/25/2018] [Indexed: 01/21/2023]
|
40
|
Trapero-Bertran M, Muñoz C, Coyle K, Coyle D, Lester-George A, Leidl R, Bertalan N, Cheung KL, Pokhrel S, Lopez-Nicolás A. Cost-effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD. Tob Prev Cessat 2018. [DOI: 10.18332/tpc/90419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
41
|
Trapero-Bertran M, Leidl R, Muñoz C, Kulchaitanaroaj P, Coyle K, Präger M, Józwiak-Hagymásy J, Cheung KL, Hiligsmann M, Pokhrel S, EQUIPT Study Group OBOT. Estimating costs for modelling return on investment from smoking cessation interventions. Tob Prev Cessat 2018. [DOI: 10.18332/tpc/90429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
42
|
Muñoz C, Risueño J, Yilmaz A, Pérez-Cutillas P, Goyena E, Ortuño M, Bernal LJ, Ortiz J, Alten B, Berriatua E. Investigations of Phlebotomus perniciosus sand flies in rural Spain reveal strongly aggregated and gender-specific spatial distributions and advocate use of light-attraction traps. Med Vet Entomol 2018; 32:186-196. [PMID: 29111588 DOI: 10.1111/mve.12275] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2017] [Revised: 09/05/2017] [Accepted: 09/17/2017] [Indexed: 06/07/2023]
Abstract
The spatial and temporal distribution of Phlebotomus perniciosus (Diptera: Psychodidae) (Newstead, 1911), the sand fly vector of pathogens of public and animal health importance, was investigated in a high sand fly density rural area in Spain using light-attraction and sticky-interception traps. Traps were placed inside animal buildings and outside at increasing distance from animals. A total of 8506 sand flies were collected, 87% with light traps. Species frequency differed between trap types. The abundance of P. perniciosus decreased exponentially with increasing distance to animals and, while females were most common in the animal enclosure, males predominated in adjoining storage places. Increasing CO2 concentration had an additional positive effect on female abundance only. Both male and female density increased with rising temperature, and there was some indication that females were more active than males at higher relative humidity. The study confirms that P. perniciosus aggregates around animal premises, although male and female distributions differ and should be analysed separately to account for biological and behavioural differences. This provides further evidence that light traps offer an accurate estimation of the relative spatial and temporal abundance of P. perniciosus, conferring an added value for the study of this species and the risk of pathogen transmission.
Collapse
Affiliation(s)
- C Muñoz
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence 'Campus Mare Nostrum', Universidad de Murcia, Murcia, Spain
| | - J Risueño
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence 'Campus Mare Nostrum', Universidad de Murcia, Murcia, Spain
| | - A Yilmaz
- Ecology Section, Department of Biology, Faculty of Science, Hacettepe University HU-ESRL-VERG Laboratories, Ankara, Turkey
| | - P Pérez-Cutillas
- Centro de Edafología y Biología Aplicada del Segura, Consejo Superior de Investigaciones Científicas (CEBAS-CSIC), Murcia, Spain
- Departamento de Geografía, Universidad de Murcia, Murcia, Spain
| | - E Goyena
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence 'Campus Mare Nostrum', Universidad de Murcia, Murcia, Spain
| | - M Ortuño
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence 'Campus Mare Nostrum', Universidad de Murcia, Murcia, Spain
| | - L J Bernal
- Departamento de Medicina y Cirugía Animal, Facultad de Veterinaria, Regional Campus of International Excellence 'Campus Mare Nostrum', Universidad de Murcia, Murcia, Spain
| | - J Ortiz
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence 'Campus Mare Nostrum', Universidad de Murcia, Murcia, Spain
| | - B Alten
- Ecology Section, Department of Biology, Faculty of Science, Hacettepe University HU-ESRL-VERG Laboratories, Ankara, Turkey
| | - E Berriatua
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence 'Campus Mare Nostrum', Universidad de Murcia, Murcia, Spain
| |
Collapse
|
43
|
Risueño J, Ortuño M, Pérez-Cutillas P, Goyena E, Maia C, Cortes S, Campino L, Bernal LJ, Muñoz C, Arcenillas I, Martínez-Rondán FJ, Gonzálvez M, Collantes F, Ortiz J, Martínez-Carrasco C, Berriatua E. Epidemiological and genetic studies suggest a common Leishmania infantum transmission cycle in wildlife, dogs and humans associated to vector abundance in Southeast Spain. Vet Parasitol 2018; 259:61-67. [PMID: 30056986 DOI: 10.1016/j.vetpar.2018.05.012] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2018] [Revised: 05/22/2018] [Accepted: 05/22/2018] [Indexed: 10/16/2022]
Abstract
Leishmania infantum infection was investigated in 202 wild carnivores, rodents and lagomorphs in Southeast Spain using a real-time PCR (rtPCR) in skin and organ samples, mostly spleen. Lesions compatible with leishmaniosis were not observed in any of the animals. Prevalence defined as the percentage of rtPCR-positive animals was 32% overall, and 45% in foxes (n = 69), 30% in rabbits (n = 80) and stone martens (n = 10), 19% in wood mice (n = 16), 0% in black rats (n = 10) and ranged between 0% and 100% in other minoritarian species including badgers, wild cats, wolves, raccoons, genets and hares. Most infected rabbits were rtPCR-positive in skin and not in spleen samples and the opposite was the case for foxes (p < 0.05). L. infantum prevalence was lowest in spring following months of non-exposure to phlebotomine sand fly vectors, and spatially matched recently estimated Phlebotomus perniciosus vector abundance and the prevalence of subclinical infection in dogs and humans. Prevalence increased with altitude and was greater in drier and less windy South and West compared to the coastal Southeast of the study area (p < 0.05). Genetic diversity of L. infantum from foxes, investigated by PCR-restriction fragment length polymorphisms of kinetoplast DNA, revealed B genotype in all animals, which is frequent in people and dogs in the Iberian Peninsula and Morocco. The study provides further evidence that subclinical L. infantum infection is widespread in wildlife with prevalence depending on environmental factors and that parasite tissue tropism may vary according to host species. Moreover, it suggests that sylvatic and domestic transmission cycles are closely interconnected.
Collapse
Affiliation(s)
- J Risueño
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence "Campus Mare Nostrum", Universidad de Murcia, 30100, Murcia, Spain
| | - M Ortuño
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence "Campus Mare Nostrum", Universidad de Murcia, 30100, Murcia, Spain
| | - P Pérez-Cutillas
- Centro de Edafología y Biología Aplicada del Segura, Consejo Superior de Investigaciones Científicas (CEBAS-CSIC), 30100, Murcia, Spain; Departamento de Geografía, Universidad de Murcia, 30001, Murcia, Spain
| | - E Goyena
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence "Campus Mare Nostrum", Universidad de Murcia, 30100, Murcia, Spain
| | - C Maia
- Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa (UNL), 1349-008, Lisboa, Portugal
| | - S Cortes
- Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa (UNL), 1349-008, Lisboa, Portugal
| | - L Campino
- Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa (UNL), 1349-008, Lisboa, Portugal
| | - L J Bernal
- Departamento de Medicina y Cirugía Animal, Facultad de Veterinaria, Regional Campus of International Excellence "Campus Mare Nostrum", Universidad de Murcia, 30100, Murcia, Spain
| | - C Muñoz
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence "Campus Mare Nostrum", Universidad de Murcia, 30100, Murcia, Spain
| | - I Arcenillas
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence "Campus Mare Nostrum", Universidad de Murcia, 30100, Murcia, Spain
| | - F J Martínez-Rondán
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence "Campus Mare Nostrum", Universidad de Murcia, 30100, Murcia, Spain
| | - M Gonzálvez
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence "Campus Mare Nostrum", Universidad de Murcia, 30100, Murcia, Spain
| | - F Collantes
- Departamento de Zoología y Antropología Física, Regional Campus of International Excellence "Campus Mare Nostrum", Universidad de Murcia, 30100, Murcia, Spain
| | - J Ortiz
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence "Campus Mare Nostrum", Universidad de Murcia, 30100, Murcia, Spain
| | - C Martínez-Carrasco
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence "Campus Mare Nostrum", Universidad de Murcia, 30100, Murcia, Spain
| | - E Berriatua
- Departamento de Sanidad Animal, Facultad de Veterinaria, Regional Campus of International Excellence "Campus Mare Nostrum", Universidad de Murcia, 30100, Murcia, Spain.
| |
Collapse
|
44
|
Ortiz AP, Tortolero-Luna G, Romaguera J, Pérez CM, González D, Muñoz C, González L, Marrero E, Suárez E, Palefsky JM, Panicker G, Unger ER. Seroprevalence of HPV 6, 11, 16 and 18 and correlates of exposure in unvaccinated women aged 16-64 years in Puerto Rico. ACTA ACUST UNITED AC 2018; 5:109-113. [PMID: 29555601 PMCID: PMC5886958 DOI: 10.1016/j.pvr.2018.03.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2017] [Revised: 02/26/2018] [Accepted: 03/15/2018] [Indexed: 12/15/2022]
Abstract
Background To understand risk factors for HPV exposure in Puerto Rican women, we evaluated HPV 6, 11, 16, and 18 serology in women aged living in the San Juan metropolitan area. Methods As part of a cross-sectional study, a population-based sample of 524 HPV unvaccinated Hispanic women ages 16–64 years completed face-to-face and computer assisted interviews and provided blood and self-collected anal and cervical specimens. Serology used multiplex virus-like particle based-IgG ELISA and HPV DNA was detected with L1-consensus PCR. Results 32% and 47% were seropositive to HPV types included in the bivalent (16/18) and quadrivalent (6/11/16/18) vaccines, respectively. Type-specific seroprevalence was HPV6 − 29%, HPV11 − 18%, HPV16 − 23%, and HPV18 − 17%; seroprevalence was high in the youngest age-group (16–19: 26–37%). HPV seropositivity was associated with having ≥ 3 lifetime sexual partners (OR=2.5, 95% CI=1.7–3.9) and detection of anogenital HPV DNA (OR=1.8, 95% CI=1.2–2.6). Conclusions The high cumulative exposure of HPV vaccine types 6/11/16/18 in this Hispanic population was influenced by factors related to HPV exposure through sexual behavior. High seroprevalence in the youngest age-group indicates early age of exposure to HPV in Puerto Rico, highlighting the need for HPV vaccination starting prior to age 16.
Collapse
Affiliation(s)
- A P Ortiz
- Cancer Control and Population Sciences Program, Comprehensive Cancer Center, University of Puerto Rico, USA; Department of Biostatistics and Epidemiology, Graduate School of Public Health, Medical Sciences Campus, University of Puerto Rico, USA.
| | - G Tortolero-Luna
- Cancer Control and Population Sciences Program, Comprehensive Cancer Center, University of Puerto Rico, USA
| | - J Romaguera
- Department of OBGYN, School of Medicine, Medical Sciences Campus, University of Puerto Rico, USA
| | - C M Pérez
- Department of Biostatistics and Epidemiology, Graduate School of Public Health, Medical Sciences Campus, University of Puerto Rico, USA
| | - D González
- Department of Biostatistics and Epidemiology, Graduate School of Public Health, Medical Sciences Campus, University of Puerto Rico, USA
| | - C Muñoz
- Cancer Control and Population Sciences Program, Comprehensive Cancer Center, University of Puerto Rico, USA
| | - L González
- Puerto Rico Clinical and Translational Research Consortium, Medical Sciences Campus, University of Puerto Rico, USA
| | - E Marrero
- Cancer Control and Population Sciences Program, Comprehensive Cancer Center, University of Puerto Rico, USA
| | - E Suárez
- Department of Biostatistics and Epidemiology, Graduate School of Public Health, Medical Sciences Campus, University of Puerto Rico, USA
| | - J M Palefsky
- University of California, San Francisco (UCSF), USA
| | - G Panicker
- Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - E R Unger
- Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
| |
Collapse
|
45
|
Julià M, Consuegra-Fernández M, Guilabert A, Muñoz C, Esteve A, Armiger-Borràs N, Santiago F, Arias M, Romaní J, Ferrándiz C, Carrascosa J, Pedrosa E, Alsina-Gibert M, Lozano F, Mascaró-Galy J. Genetically defined variants of toll-like receptors 3, 7 and 9 as phenotype and risk modifier factors for psoriasis. J Dermatol Sci 2018; 89:301-304. [DOI: 10.1016/j.jdermsci.2017.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2017] [Revised: 11/19/2017] [Accepted: 12/11/2017] [Indexed: 10/18/2022]
|
46
|
Santasusagna S, Moreno I, Navarro A, Muñoz C, Martinez F, Hernández R, Castellano JJ, Monzo M. miR-328 mediates a metabolic shift in colon cancer cells by targeting SLC2A1/GLUT1. Clin Transl Oncol 2018; 20:1161-1167. [PMID: 29374351 PMCID: PMC6105238 DOI: 10.1007/s12094-018-1836-1] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Accepted: 01/09/2018] [Indexed: 12/22/2022]
Abstract
Purpose Increasing evidence shows that altered metabolism is a critical hallmark in colon cancer. There is a strong need to explore the molecular mechanisms underlying cancer metabolism. Whether the aberrant expression of microRNAs contributes to cancer metabolism is not fully understood. miR-328 is a putative potential target of SLC2A1, but the regulating mechanism between them remains unknown. We have examined whether miR-328 directly regulates SLC2A1/GLUT1 expression in colon cancer cells. Methods We performed in silico bioinformatic analyses to identify miR-328-mediated molecular pathways and targets. We also performed luciferase assays and western blot analyses in LOVO and SW480 colon cancer cell lines. In addition, we assessed miR-328 expression in 47 paired tumor and normal tissue specimens from resected colon cancer patients. Results Luciferase reporter assays showed that miR-328 directly targeted SLC2A1 3′-untranslated region (UTR), with a significant decrease in luciferase activity in both LOVO and SW480 cell lines. These results were validated by western blot. miR-328 expression was significantly downregulated in tumor tissue compared with paired normal tissue. Conclusions Our results show that miR-328 targets SLC2A1/GLUT1. We suggest that miR-328 may be involved in the orchestration of the Warburg effect in colon cancer cells. Furthermore, miR‐328 expression is reduced in colon cancer patients and thus inversely correlates with the classically reported upregulated SLC2A1/GLUT1 expression in tumors.
Collapse
Affiliation(s)
- S Santasusagna
- Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
| | - I Moreno
- Department of Medical Oncology and Surgery, Hospital Municipal de Badalona, Badalona, Spain
| | - A Navarro
- Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
| | - C Muñoz
- Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
| | - F Martinez
- Department of Medical Oncology and Surgery, Hospital Municipal de Badalona, Badalona, Spain
| | - R Hernández
- Department of Medical Oncology and Surgery, Hospital Municipal de Badalona, Badalona, Spain
| | - J J Castellano
- Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain
| | - M Monzo
- Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain. .,Unit of Human Anatomy and Embryology, School of Medicine, Hospital Clinic, University of Barcelona, Casanova 143, 08036, Barcelona, Spain.
| |
Collapse
|
47
|
Santasusagna S, Navarro A, Moreno I, Ibeas R, Martinez F, Castellano J, Muñoz C, Canals J, Morales S, Hernandez R, Moreno J, Monzo M. Exosomal ECM1 protein expression in plasma from the tumor-draining vein (mesenteric vein) and time to relapse in colon cancer patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Navarro A, Santasusagna S, Vinolas Segarra N, Castellano J, Moises J, Morales S, Canals J, Muñoz C, Ramírez J, Marrades R, Molins L, Monzo M. HOXA-related long non-coding RNAs impact prognosis in early stage NSCLC patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx381.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Fasce G, Crispi F, Muñoz C, Zavala M, Briceño C, Castillo N, Araya N. FUNCTIONAL STATUS CHANGE AS A MORTALITY PROGNOSTIC FACTOR IN HOSPITALIZED ELDERS: CASE-CONTROL STUDY. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.1107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- G. Fasce
- Geriatrics Section, Hospital Clinico de la Universidad de Chile, Santiago, Chile
| | - F. Crispi
- Geriatrics Section, Hospital Clinico de la Universidad de Chile, Santiago, Chile
| | - C. Muñoz
- Geriatrics Section, Hospital Clinico de la Universidad de Chile, Santiago, Chile
| | - M. Zavala
- Geriatrics Section, Hospital Clinico de la Universidad de Chile, Santiago, Chile
| | - C. Briceño
- Geriatrics Section, Hospital Clinico de la Universidad de Chile, Santiago, Chile
| | - N. Castillo
- Geriatrics Section, Hospital Clinico de la Universidad de Chile, Santiago, Chile
| | - N. Araya
- Geriatrics Section, Hospital Clinico de la Universidad de Chile, Santiago, Chile
| |
Collapse
|
50
|
Muñoz C, Wills DA, Yan T. Effects of dietary active dried yeast (Saccharomyces cerevisiae) supply at two levels of concentrate on energy and nitrogen utilisation and methane emissions of lactating dairy cows. Anim Prod Sci 2017. [DOI: 10.1071/an15356] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Twenty early lactation dairy cows were used to evaluate the effects of the dietary addition of an active dried yeast product at two levels of concentrate on productive performance, nutrient digestibility, methane (CH4) emissions and energy and nitrogen utilisation. This study was a replicated 4 × 4 Latin square design with a two (concentrate level) × two (yeast supplement) factorial treatment arrangement, with four periods (6 week/period) and a 3-week interval between each period. Cows were offered grass silage-based diets consisting of two levels of concentrate (300 and 600 g/kg), with or without supplement of 0.5 g/day of an active dry yeast (Saccharomyces cerevisiae strain) with a specification of 2 × 1010 cfu/g. Feed dry matter intake, milk yield, milk composition, bodyweight and body condition score were similar between yeast treatments at both concentrate levels. Nutrient digestibility was not affected by yeast supplementation. Energy intake and faecal, urinary, CH4 and milk energy outputs were also not affected by yeast supplementation. Yeast supplementation had no effects on energy partitioning but tended to increase heat production and decreased energy retention. Yeast supplementation at two levels of concentrate had no effect on total CH4 emissions, but tended to increase CH4 per unit of feed intake and CH4 energy output per unit of gross energy intake. There were no effects of yeast supplementation on CH4 per unit of milk yield. Yeast supplementation had no effect on any variable of nitrogen intake, output or utilisation. Overall, the dietary addition of an active dried yeast product at two concentrate feeding levels had no effects on feed intake, milk production, milk composition, nutrient digestibility, or nitrogen utilisation efficiency and only tended to increase heat production, CH4 per unit of feed intake and CH4 energy output per unit of gross energy intake in lactating dairy cows.
Collapse
|